This disclosure relates generally to a configurable collimator that is controlled using linear motors.
Particle therapy systems use an accelerator to generate a particle beam for treating afflictions, such as tumors. In operation, particles are accelerated in orbits inside a cavity in the presence of a magnetic field, and are removed from the cavity through an extraction channel. A magnetic field regenerator generates a magnetic field bump near the outside of the cavity to distort the pitch and angle of some orbits so that they precess towards, and eventually into, the extraction channel. A beam, comprised of the particles, exits the extraction channel.
A scanning system is down-beam of the extraction channel. In this context, “down-beam” means closer to an irradiation target (here, relative to the extraction channel). The scanning system moves the particle beam across at least part of the irradiation target to expose various parts of the irradiation target to the particle beam. For example, to treat a tumor, the particle beam may be “scanned” over different cross-sectional layers of the tumor.
The particle beam can damage healthy tissue adjacent to the irradiation target. A structure defining an edge may be used to limit exposure of the healthy tissue to the particle beam. For example, the structure, or a portion thereof, may be placed in between the particle beam and the healthy tissue, thereby preventing exposure of the healthy tissue to the particle beam.
An example device for trimming a particle beam comprises: structures comprised of material that blocks passage of the particle beam, with the structures being configurable to define an edge that is movable into a path of the particle beam such that a first part of the particle beam on a first side of the edge is blocked by the structures and such that a second part of the particle beam on a second side of the edge is not blocked by the structures; and linear motors that are controllable to configure the structures to define the edge. Each of the linear motors comprises a movable component and a stationary component, with the stationary component comprising a magnetic field generator to generate a first magnetic field, and with the movable component comprising one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component. The movable component of each linear motor is connected to, or part of, a corresponding one of the structures such that the corresponding structure moves along with movement with the movable component. The example device may also include one or more of the following features, either alone or in combination.
The magnetic field generator may comprise magnets having like poles that are aligned, with the one or more coils being at least partly between the magnets. The example device may comprise one or more processing devices to control the linear motors to configure the structures. The one or more processing devices may be controllable to output one or more control signals to control one or more of the linear motors to extend or to retract one or more of the structures to define the edge. The one or more processing devices may be at least partly shielded from exposure to environmental neutron radiation impacting the structures and the linear motors during operation of the device. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices remotely from the structures and the linear motors. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices in a different room from the structures and the linear motors.
The example device may comprise encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures. The encoders may comprise electronic devices that are connected to a same assembly as the structures and the linear motors. The encoders may comprise one or more of laser sensors, optic sensors, or diode sensors.
The structures may comprise leaves and each magnetic field generator may comprise a pair of magnets, with each leaf being between a corresponding pair of magnets. The example device may comprise a first carriage configured to move in a first dimension, with the first carriage holding the structures and the linear motors; and a second carriage configured to move in a second dimension that is different from the first dimension, with the first carriage being coupled to the second carriage. The structures may be movable also in the first dimension relative to, and separate from movement of, the first carriage. The structures may define a first edge, and the device may further comprise: second structures that are configurable to define a second edge that is movable into a path of the particle beam such that a third part of the particle beam on a first side of the second edge is blocked by the second structures and such that a fourth part of the particle beam on a second side of the second edge is not blocked by the second structures; and second linear motors that are controllable to configure the second structures to define the second edge. The device further may further comprise a third carriage that is movable in the first dimension and that is coupled to the second carriage, with the third carriage holding the second structures and the second linear motors. The second structures may be movable also in the first dimension relative to, and separate from movement of, the third carriage. The first carriage and the third carriage may be controllable to trim a single spot of the particle beam, with the single spot corresponding to a cross-sectional area of the particle beam. The first carriage and the third carriage may be controllable to trim an area having a size that covers multiple spots of the particle beam, with a spot corresponding to a cross-sectional area of the particle beam. The first carriage and the third carriage may be configured to move independently.
An example device to trim a particle beam comprises: a first carriage that is movable in a first dimension; second carriages that are coupled to the first carriage and therefore movable in the first dimension along with the first carriage, with each of the second carriages also being movable in a second dimension that is different from the first dimension. A second carriage among the second carriages comprises: structures comprised of material that blocks passage of the particle beam, with the structures being configurable to define an edge that is movable into a path of the particle beam such that a first part of the particle beam on a first side of the edge is blocked by the structures and such that a second part of the particle beam on a second side of the edge is not blocked by the structures; and linear motors to configure the structures to define the edge, with each of the linear motors being controllable to drive a corresponding one of the structures linearly in the second dimension towards, or away from, the second carriage. The example device may comprise one of more of the following features, either alone or in combination.
A linear motor among the linear motors may comprise a movable component and a stationary component, with the stationary component comprising a magnetic field generator to generate a first magnetic field, and with the movable component comprising one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component. The movable component of the linear motor may be connected to, or part of, a corresponding one of the structures such that the corresponding structure moves along with movement with the movable component. The magnetic field generator may comprise magnets having like poles that are aligned, with the one or more coils being at least partly between the magnets.
The example device may comprise one or more processing devices to control the linear motors to configure the structures. The one or more processing devices may be controllable to output one or more control signals to control one or more of the linear motors to extend or to retract one or more of the structures in the second dimension to define the edge, with the one or more processing devices being shielded from exposure to environmental neutron radiation impacting the structures and the linear motors during operation of the device. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices remotely from the structures and the linear motors. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices in a different room from the structures and the linear motors.
The example device may comprise encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures. The encoders may comprise electronic devices that are more tolerant than the one or more processing devices to exposure to the neutron radiation impacting the structures and the linear motors during operation of the device. The encoders may comprise one or more of laser sensors, optic sensors, or diode sensors.
An example particle therapy system comprises: a particle accelerator to output a particle beam, with the particle accelerator generating neutron radiation in an enclosed treatment space during operation; one or more scanning magnets to move the particle beam relative to an irradiation target in a patient; and a device to trim the particle beam, with the device being between the one or more scanning magnets and the patient. The device comprises structures comprised of material that blocks passage of the particle beam, with the structures being configurable to define an edge that is movable into a path of the particle beam such that a first part of the particle beam on a first side of the edge is blocked by the structures and such that a second part of the particle beam on a second side of the edge is not blocked by the structures; and linear motors that are controllable to configure the structures by driving the structures linearly to define the edge. One or more processing devices are configured to control operation of the device to trim the particle beam, with the one or more processing devices being located in an area that is exposed to less than a specified amount of the neutron radiation. The example particle therapy system may comprise one or more of the following features, either alone or in combination.
The area may be a room that is external to the enclosed treatment space. The enclosed treatment space may be at least partly shielded to reduce exposure of the room to the neutron radiation. A linear motor among the linear motors may comprise a movable component and a stationary component, with the stationary component comprising a magnetic field generator to generate a first magnetic field, and with the movable component comprising one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component. The movable component of the linear motor may be connected to, or part of, a corresponding one of the structures such that the corresponding structure moves along with movement with the movable component to drive the corresponding structure linearly. The magnetic field generator may comprise magnets having like poles that are aligned, with the one or more coils being at least partly between the magnets.
The device may comprise encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures, with the encoders being within the enclosed treatment space and subjected to the neutron radiation. The encoders may comprise one or more of laser sensors, optic sensors, or diode sensors. The structures may comprise leaves and each magnetic field generator may comprise a pair of magnets, with each leaf being between a corresponding pair of magnets.
The particle accelerator may be, or include, a synchrocyclotron. The particle therapy system may comprise a gantry on which at least the synchrocyclotron is mounted, with the gantry being movable relative to the patient to move the synchrocyclotron relative to the patient.
The synchrocyclotron may comprise: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a particle source, with the voltage source being controlled to sweep the RF voltage over a frequency range in a cycle; a coil to receive electrical current having one of multiple values and to generate a magnetic field corresponding to the electrical current, with the magnetic field for causing the particles to move orbitally within the cavity at an energy that corresponds to the electrical current, the magnetic field being at least 4 Tesla; and an extraction channel to receive the particles from the cavity and to output the particles received from the cavity to the scanning system, with the particles that are output from the cavity having an energy that is based on the electrical current. The synchrocyclotron may be configured to enable setting of the electrical current to one of the multiple values, with each of the multiple values corresponding to a different energy at which particles are output from the cavity. The voltage source may be controllable to sweep the RF voltage over a different frequency ranges, with each different frequency range corresponding to each different energy at which the particles are output from the cavity.
The synchrocyclotron may comprise: a particle source for holding ionized plasma, with the particle source being in a cavity and comprising two parts that are separated at an acceleration region; a voltage source to provide a radio frequency (RF) voltage to the cavity to accelerate particles from the ionized plasma at a separation region of the particle source, with the voltage source being controllable to sweep the RF voltage over a frequency range in a cycle; a coil to receive electrical current to generate a magnetic field based on the electrical current, with the magnetic field for causing the particles to move orbitally within the cavity, with the magnetic field in the cavity being a maximum of 4 Tesla or more; at least one magnetic pole piece, with the at least one magnetic pole piece comprising ferromagnetic material that borders the cavity; and an extraction channel to receive the particles from the cavity and to output the particles received towards the one or more scanning magnets.
An example device for trimming a particle beam comprises: structures comprised of material that blocks passage of the particle beam, with the structures being configurable to define an edge that is movable into a path of the particle beam; and linear motors that are controllable to configure the structures to define the edge. The example device may comprise one or more of the following features, either alone or in combination.
The example device may comprise one or more processing devices to control the linear motors to configure the structures. The one or more processing devices may be controllable to output one or more control signals to control one or more of the linear motors to extend or to retract one or more of the structures to define the edge. The one or more processing devices may be at least partly shielded from exposure to environmental neutron radiation impacting the structures and the linear motors during operation of the device. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices remotely from the structures and the linear motors. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices in a different room from the structures and the linear motors.
The example device may comprise encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures. The encoders may comprise electronic devices that are connected to a same assembly as the structures and the linear motors. The encoders may comprise one or more of laser sensors, optic sensors, or diode sensors.
Two or more of the features described in this disclosure, including those described in this summary section, may be combined to form implementations not specifically described herein.
Control of the various systems described herein, or portions thereof, may be implemented via a computer program product that includes instructions that are stored on one or more non-transitory machine-readable storage media, and that are executable on one or more processing devices (e.g., microprocessor(s), application-specific integrated circuit(s), programmed logic such as field programmable gate array(s), or the like). The systems described herein, or portions thereof, may be implemented as an apparatus, method, or electronic system that may include one or more processing devices and computer memory to store executable instructions to implement control of the stated functions.
The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.
Like reference symbols in the various drawings indicate like elements.
Described herein are example implementations of a configurable collimator that may be used to control the extent of radiation, such as a proton or ion beam, applied to a patient. In this regard, a configurable collimator includes a structure that is controllable to allow some radiation to pass to a patient and to block some radiation from passing to the patient. Typically, the radiation that passes is directed to an irradiation target to be treated, and the radiation that is blocked would otherwise hit, and potentially damage, healthy tissue. In operation, the configurable collimator is placed in the radiation path between a radiation source and an irradiation target and is controlled to produce an opening of an appropriate size and shape to allow some radiation to pass through the opening to the irradiation target, while a remainder of the structure blocks some radiation from reaching adjacent tissue. The configurable collimator may be used in any appropriate radiation therapy system, and is not limited to use with any particular type of system.
In some implementations, the configurable collimator contains generally flat structures, which are referred to as “plates” or “leaves”, and which are controllable to move into the “beam” or “treatment” area to block passage of some radiation and allow passage of other radiation. In some implementations, there are two sets of leaves that face each other. The sets of leaves are controllable to produce an opening of size and shape that is appropriate for treatment. For example, each set of leaves is configurable to define an edge that is movable into a path of the particle beam so that a first part of the particle beam on a first side of the edge is blocked by the leaves, and so that a second part of the particle beam on a second side of the edge is not blocked by the leaves and is allowed to pass to the treatment area. In some implementations the leaves are connected to, are part of, or include, linear motors—one per leaf—that are controllable to control movement of the leaves towards or away from the treatment area to define the edge.
In some implementations, the linear motors are controllable to configure a set of leaves to define a first edge, and to configure another set of leaves to define a second edge that faces the first edge. As described herein, each of the linear motors may include a movable component and a stationary component. The stationary component includes a magnetic field generator to generate a first magnetic field. An example of a magnetic field generator includes two stationary magnets that are adjacent and spaced apart, and that have their poles aligned. The movable component includes one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component. For example, the movable component may be a coil-carrying plate between the two magnets that make up the stationary component. When current passes through the coil, that current produces a magnetic field that interacts with the magnetic field produced by the two magnets, and that causes the movable component (e.g., the current-carrying plate) to move relative to the two magnets. Because a leaf is attached to the movable component, the leaf moves along with the movable component. The linear motors of different leaves may be controlled to control movement of the leaves, and thus to define the edges of the configurable collimator described above.
As noted, in some implementations, a linear motor includes two magnets that are adjacent and spaced apart and that have their poles aligned, and a coil-carrying plate that is sandwiched between the two magnets and that moves relative to the two magnets. This configuration allows multiple linear motors to be arranged in a row, each in close proximity to the next, as may be required to control leaves of the configurable collimator. For example, in some implementations, the leaves are on the order of millimeters thick (e.g., five millimeters or less). Leaves of this thickness enable relatively high precision edges; however, leaves of this thickness may make implementation using other types of motors impractical in some cases. However, the linear motors described herein enable use of leaves having thicknesses of this magnitude. For example, the two stationary magnets shield the coil-carrying plate that moves between them, thereby controlling movement of the leaves. By shielding the coil-carrying plate from stray magnetic fields, it is possible to control movement of the plates even when multiple coil-carryings and corresponding stationary magnets are close proximity to each other.
In some implementations, a computing system, which may be comprised of one or more processing devices, is programmed to control the linear motors to thereby control positioning of leaves to define an edge. For example, the computing system may be controllable to output one or more control signals to control one or more of the linear motors to extend or to retract one or more of the leaves to define the edge. The computing system is at least partly shielded from exposure to environmental neutron radiation impacting leaves and the linear motors during particle therapy. More specifically, application of particle therapy causes stray neutrons to be present in the treatment room (e.g., a proton center). Stray neutrons can have a deleterious effect on electronics and, therefore, it is beneficial to shield those electronics from the neutrons. For example, processing devices, such as microprocessors, microcontrollers, field-programmable gate arrays (FPGAs), applications-specific circuits (ASICs), and so forth can be susceptible to environmental neutron radiation. Accordingly, in some implementations, the computing system is shielded by locating the computing system remotely from the source of the neutron radiation. For example, the computing system may be shielded by locating the computing system remotely from the collimation device, including the linear motors, that are controlled by the computing system. In some examples, the computing system may be located in a different room from where treatment occurs. The room may be appropriately shielded to reduce, or to prevent, the effects of neutron radiation on the computing system.
In some implementations, motion of the linear motors may be tracked using encoders. In some examples, encoders include electronic devices that are connected to a same assembly as the leaves and the linear motors. The encoders may include or more of laser sensors, optic sensors, or diode sensors. The encoders detect movement of the leaves, e.g., by detecting where markings or other indicia on the leaves, or on structures that are connected to and that move with the leaves, are located relative to the encoders. Information about locations of the leaves is fed back to the computing system, and is used by the computing system to confirm the position of the leaves during operation and, in some implementations, to change their position. The encoders may be, or include, simple electronic sensors that are not as sensitive to neutron radiation as the processing devices above and that, therefore, may be located in the treatment room.
In
In some implementations, the configurable collimator leaves have a height that is sufficient to block at least the maximum beam energy (e.g., the maximum energy of the particle beam output by the system). In some implementations, the configurable collimator leaves have a height that blocks less than the maximum beam energy. In some implementations, the configurable collimator leaves have lengths that are dictated not by the area of an entire treatment area, but rather by the area of a single beam spot or multiple beam spots. In this context, a “beam spot” is the cross-sectional area of a particle beam.
In some implementations, the particle therapy system may be configured to treat a tumor having a cross-section that can fit into a 20 cm×20 cm square area. In this example, each leaf in the configurable collimator may have a length of about 2 cm, which is about enough to block particles in half of one beam spot. As noted, the configurable collimator includes sets of leaves that face each other. So, leaves from each set may be controlled to cover the whole, single beam spot, if necessary, thereby preventing passage of radiation. The leaves may also be controllable to create an opening through which some, or all, of the radiation from the single beam spot can pass.
In operation, the configurable collimator is configured to move as the beam scans across the radiation target, and to track the beam's movement during scanning. In this example, the configurable collimator may be configured to move about 20 cm so as to enable coverage over the entirety of the 20 cm×20 cm area. As described above, the configurable collimator may be configured to use enough leaves to cover (or “trim”) one beam spot and, in some case, a small amount of extra area (e.g., 5% extra area, 10% extra area, 15% extra area, or 20% extra area).
Leaves 201 are mounted on carriages to control their movement relative to a treatment area of an irradiation target, such as a cross-sectional layer of a tumor in a patient. The movement is controlled to cause leaves 201 to cover some parts of treatment area 204, thereby preventing radiation from impacting those parts during treatment, while leaving other parts of treatment area exposed to the radiation. In the example implementation of
The configurable collimator may be used with any appropriate type of radiation therapy system. In an example implementation, the radiation therapy system is a proton therapy system. As described herein, an example proton therapy system scans a proton beam across a treatment area of an irradiation target in order to destroy malignant tissue. During scanning, the particle beam moves across the treatment area to cover the treatment area with radiation. In an example implementation, the particle beam is pulsed. Because the particle beam is pulsed, the affected parts of the treatment area constitute a series of spots, one for each pulse that hits the treatment area. Depending upon the size of the beam, the result may leave some areas untreated. As a result, it may be beneficial to scan the same treatment area more than once in order to ensure that the entire area is treated. Each successive scan may be offset from the other(s) in order to hit all areas. An example of this type of scanning is called pencil-beam scanning, and the repetitive scans are referred to as painting or repainting the treatment area.
The irradiation target is typically three-dimensional in structure. Accordingly, as described herein, the irradiation target is treated cross-sectional layer (or simply “layer”) by layer. That is, a layer of the irradiation target is treated, followed by another treatment of another layer, and so forth until the entire target is treated. Different layers of an irradiation target are treated by varying an energy level of the particle beam. That is, different energy levels of the particle beam impact different layers of the irradiation target, with higher energy levels affecting layers deeper inside the irradiation target relative to the particle beam source. Accordingly, during treatment, the energy level of the particle beam is changed in order to reach, and thus treat, different layers of the irradiation target.
In an example implementation, on each of two separate carriages, there are five leaves that are about 5 mm in width and two leaves that are about 20 mm in width. In some implementations, on each of two separate carriages, there are seven leaves, two of which each have widths that are three times or more the widths of each of five other leaves. Other implementations may contain different numbers, sizes, and configurations of leaves, and different numbers and configurations of carriages. For example, some implementations may include any number between five and fifty leaves per carriage, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 leaves (or more) per carriage.
The carriages can move both horizontally and vertically, as described herein. The leaves are also movable horizontally relative to each carriage into, and out of, the treatment area. In this way, the leaves are configurable to approximate the shape of the treatment boundary in the region near the area being treated (e.g., circle 211 or a portion thereof in this example).
The leaves may be moved vertically and/or horizontally between different scans of the particle beam so that the leaves are in appropriate positions when the beam is delivered to a particular area. The leaves need not necessarily be moved for every scan pass, but instead may be moved to a location appropriate for an area. In some cases, e.g., for spots interior to the treatment area, radiation treatment may proceed without the trimming provided by the configurable collimator.
Carriage 413 is referred to herein as the primary carriage, and carriages 414 and 415 are referred to herein as secondary carriages. Secondary carriages 414, 415 are coupled to primary carriage 413, as shown in
As shown in
As shown in
In this example implementation, as noted, seven leaves 435, 436 are mounted on each secondary carriage 414, 415. Each secondary carriage may be configured to move its leaves horizontally into, or out of, the treatment area. The individual leaves on each secondary carriage may be independently and linearly movable, using linear motors, in the X dimension relative to other leaves on the same secondary carriage. In some implementations, the leaves may also be configured to move in the Y dimension. Furthermore, the leaves on one secondary carriage 414 may be movable independently of the leaves on the other secondary carriage 415. These independent movements of leaves on the secondary carriages, together with the vertical movements enabled by the primary carriage, allow the leaves to be moved into various configurations. As a result, the leaves can conform, both horizontally and vertically, to treatment areas that are randomly shaped both in horizontal and vertical dimensions. The sizes and shapes of the leaves may be varied to create different conformations.
The leaves may be made of any appropriate material that prevents or inhibits transmission of radiation. The type of radiation used may dictate what material(s) are used in the leaves. For example, if the radiation is X-ray, the leaves may be made of lead. In the examples described herein, the radiation is a proton or ion beam. Accordingly, different types of metals or other materials may be used for the leaves. For example, the leaves may be made of nickel, tungsten, lead, brass, steel, iron, or any appropriate combinations thereof. The height of each leaf may determine how well that leaf inhibits transmission of radiation.
In some implementations, the leaves may have the same height, whereas in other implementations, some of the leaves may have heights that are different from heights of others of the leaves. For example, in
In some implementations, shorter leaves (e.g., leaves of lesser height) may be used in connection with longer leaves. In some implementations, the leaves have enough height to completely block the particle beam at the maximum beam energy. In some implementations, the leaves have enough height to block the particle beam at less than the maximum beam energy (and not to block the particle beam at maximum energy). For example, while a proton therapy system may have the capability to deliver a beam of energy 230 MeV that can treat to a depth in the patient of 32 cm, in some implementations, the configurable collimator can only block protons of at most 175 MeV that can treat to a depth of no more than 20 cm. In doing so, less beam-stopping material may be used, e.g., 2.1 cm of Tungsten instead of 3.3 cm, or 3.3 cm of Nickel instead of 5.2 cm. In this example, the proton therapy system would still be capable of treating at depths exceeding 20 cm, but the configurable collimator would not be used for such treatments. This may be deemed acceptable because, in some circumstances, deeper treatments benefit less from the example particle beam collimation that the configurable collimator provides. That is, in some treatment scenarios, shallow, low-energy treatments are where the configurable collimator will be most effective, and there may be engineering advantages to reducing the amount of material in the leaves. Thus, in some example implementations, the configurable collimator may be restricted to use with shallow, lower-than-maximum energy treatments.
In the implementations of
In some implementations, the leaves have heights that are enough not only to fully stop a particle beam at the maximum expected proton energy (e.g., 3.3 cm of Tungsten at 230 MeV or, e.g., 5.2 cm of nickel), but also to have enough extra material to prevent proton transmission between the leaves. This material may have a tongue and groove structure as shown in
In some implementations, there may be more than one primary carriage and corresponding motors and rails. For example, a first primary carriage may control vertical movement of a first secondary carriage, and a second primary carriage may control vertical movement of a second secondary carriage. Therefore, in such implementations, the two secondary carriages can be moved independently in the vertical dimension, if desired. In any case, the primary carriage may be computer controlled. For example, executable instructions are stored in computer memory (e.g., one or more non-transitory machine-readable storage media), and executed by one or more processing devices to control the movement. Control may be performed with, or without, user input during treatment.
As explained, each secondary carriage 414, 415 includes a corresponding motor to control horizontal carriage movement, as described above. In some implementations, all leaves on a single carriage are independently movable using linear motors—with one linear motor controlling each leaf.
Taking leaf 702 as an example, an example linear motor that controls operation of leaf 702 includes a movable component and stationary component comprised of two parts—in this example, magnets 710a and 710b. The two magnets are arranged side-by-side, with their poles aligned. That is, as shown, the positive pole (+) of magnet 710a is aligned to the positive pole (+) of magnet 701b, and the negative pole (−) of magnet 701a is aligned to the negative pole (−) of magnet 710b. The movable component comprises a coil-carrying plate 709 between magnets 710a and 710b. Coil-carrying plate 709 is connected, physically, to leaf 702, and controls movement of leaf 702 along the directions of arrow 711, e.g., into and out of a treatment area, to form part of an edge of the configurable collimator.
As explained, coil-carrying plate 709 includes one or more conductive traces or other conductive structures, that pass current in order to generate a magnetic field. The magnetic field is controlled by controlling the current through the coil-carrying plate in order to control movement of the coil carrying plate, and thus of the leaf 702. That is, current through the coils generates a magnetic field that interacts with the magnetic field produced by magnets 710a and 710b. This interaction causes movement of coil carrying plate 709 and of leaf 702 along a direction of arrow 711, either into, or out of, the treatment area. For example, larger magnetic fields generated by the coil-carrying plate 709 may cause the leaf to move into the treatment area, and smaller magnetic fields generated by the coil-carrying plate may cause the leaf to retract away from the treatment area.
In some implementations, the conductive traces or other conductive structures on the coil-carrying plate may include three windings embedded in aluminum. In some implementations, the leaf may be made of nickel, and be physically attached to the coil-carrying plate. In some implementations, the number of windings and the materials used may be different than those described herein. In some implementations, the coil-carrying plate may be an integral part of the leaf. That is, the leaf itself may include the conductive structures or traces.
In some implementations, the linear motors may include a bearing rod for each leaf. In some implementations, the bearing rod may be between the coil-carrying-plate and the leaf to guide movement of the leaf.
As shown in
In this regard, encoders (not shown) may include or more of laser sensors, optic sensors, or diode sensors. The encoders detect movement of the leaves, e.g., by detecting where markings or other indicia on the leaves or on structures connected to, and that move with, the leaves are located relative to the encoders. This information about where the leaves are is fed back to the computing system, and is used by the computing system to confirm the position of the leaves during operation. The encoders may be located at any appropriate location. In some implementations, the encoders are located on a housing that includes the leaves. As the leaves move, markings or other indicia that move with the leaves move past the encoders. The encoders then relay that information to computing system 714. Computing system 714 may use that information to control operation of the configurable collimator, including positioning the leaves.
Adding rotational degrees of freedom can improve the ability of the configurable collimator to conform to radiation targets. For example, the entirety of the assembly of
In the example implementations described above, each leaf is independently actuatable using a separate, and independently-controllable, linear motor such that any appropriate shape can be traced with a leaf configuration. It may be, however, that such flexibility is not required to achieve acceptable edge conformality. The leaves could be mechanically constrained with the ability to achieve only a finite number of configurations. For example, the leaves could be restricted to arrangements that put them in a vertical line, forward diagonal shape, backward diagonal shape, concave shape, convex shape, or any other achievable shape. In this way, flexibility could be traded for mechanical simplicity.
The configurable collimator may be used to collimate edges that are completely internal to the treatment/beam field. If a treatment plan calls for a volume to be treated that completely surrounds a volume to be protected—for example, a tumor that completely surrounds a spinal cord—a single, machined structure will typically be unable to block radiation to the protected volume without blocking some of treated volume as well. The configurable collimator can treat such a field using a sequence of leaf positions. For example, the configurable collimator can be reconfigured dynamically, and during treatment, to protect the areas that require protection, while allowing treatment on areas that require treatment.
In some cases, better beam performance (penumbra or edge sharpness) results when the particle beam is tangent to the surface of a leaf edge. However, since the beam effectively originates from a single point source, the angle with which it passes through the plane of the configurable collimator changes as the beam is moved away from the center of the field. For this reason, leaves may have curved edges, as shown in
To summarize, in some implementations, the configurable collimator may have a relatively small size, at least in part due to the linear motors described herein. Thus, in contrast to standard multi-leaf collimators, an example configurable collimator may therefore be used to trim a fraction of a treatment area at one time, e.g., an area that is less than the entire treatment area and that is about equal to one spot size, two spot sizes, three spots sizes, four spot sizes, five spot sizes, and so forth. Thus, in some implementations, the configurable collimator may be small enough to trim a single spot at once and may be large enough to trim several spots in one position, but not the entire field without moving. Thus, the configurable collimator may be configured to move around and within the field as the beam scans. That is, in some implementations, the configurable collimator tracks the beam as it scans, and its configuration and reconfiguration may be synchronized to the scanning and to the pulses provided by the beam (e.g., different reconfigurations for different beam pulses and/or locations). By not using leaves large enough to trim an entire treatment area, the configurable collimator can be made smaller and therefore the configurable collimator can be placed closer to the patient with little or no interference from other devices. In some implementations, no leaf of the configurable collimator even has one dimension that spans an entire maximum treatment area. In some implementations, each individual leaf is movable in two dimensions within the treatment area, and the device is mounted on a gantry (e.g., in the context of a particle therapy system such as that described herein) to be rotated on one or more axes and made extendable towards and away from isocenter.
Furthermore, as described herein, use of linear motors to control the leaves enables further reductions in collimator size. In particular, linear motors having stationary magnets and a movable coil-carrying plate enables the leaves to be stacked relatively close together, which enables individual spot trimming, e.g., trimming in the millimeter range. Heretofore, in known linear motors, current-carrying plates were stationary. However, in some cases, that configuration may not be amenable to stacking leaves of the sizes described herein at least because magnetic fields from the stationary current-carrying plates affect adjacent linear motors, thereby leading to less accurate operation or more system complexity to address these adjacent fields. In any case, the known configurations were not conducive to stacking and controlling leaves of the sizes used in the configurable collimator described herein.
A scanning system includes the configurable collimator describe herein, which is placeable relative to the irradiation target to limit the extent of the particle beam and thereby limit the extent of the particle beam. For example, the configurable collimator may be placed in the beam path down-beam of the energy degrader and before the particle beam hits the treatment area of the irradiation target. The configurable collimator is controllable to allow the particle beam to pass therethrough and then hit certain parts of the treatment area, while preventing the particle beam from hitting other parts of the patient. As noted, the configurable collimator may be controlled to prevent the particle beam from hitting healthy tissue or to prevent the particle beam from hitting other parts of the irradiation target (e.g., if certain parts of the target are to receive more radiation than other parts).
As noted, the configurable collimator may be part of, or used with, a scanning system in a particle therapy system.
In some implementations, the particle accelerator includes a particle source 1217 (e.g., a Penning Ion Gauge—PIG source) to provide an ionized plasma column to the cavity 1216. Hydrogen gas, or a combination of hydrogen gas and a noble gas, is ionized to produce the plasma column. A voltage source provides a varying radio frequency (RF) voltage to cavity 16 to accelerate pulses of particles from the plasma column within the cavity. The magnetic field in the cavity is shaped to cause particles to move orbitally within the cavity. In some implementations, the maximum magnetic field produced by the superconducting coils may be within the range of 4 Tesla (T) to 20T, as explained herein. The example synchrocyclotron employs a magnetic field that is uniform in rotation angle and falls off in strength with increasing radius. In some implementations, such a field shape can be achieved regardless of the magnitude of the magnetic field.
As noted, in an example, the particle accelerator is a synchrocyclotron. Accordingly, the RF voltage is swept across a range of frequencies to account for relativistic effects on the particles (e.g., increasing particle mass) when accelerating particles within the acceleration cavity. The magnetic field produced by running current through the superconducting coils, together with the shape of the cavity, causes particles accelerated from the plasma column to accelerate orbitally within the cavity and to increase in energy with an increasing number of turns.
As noted, the superconducting coils (called the main coils) can produce relatively high magnetic fields. In an example implementation, the maximum magnetic field generated by a main coil (e.g., at the center of the acceleration cavity) may be within a range of 4T to 20T or more. For example, the superconducting coils may be used in generating magnetic fields at, or that exceed, one or more of the following magnitudes: 4.0T, 4.1T, 4.2T, 4.3T, 4.4T, 4.5T, 4.6T, 4.7T, 4.8T, 4.9T, 5.0T, 5.1T, 5.2T, 5.3T, 5.4T, 5.5T, 5.6T, 5.7T, 5.8T, 5.9T, 6.0T, 6.1T, 6.2T, 6.3T, 6.4T, 6.5T, 6.6T, 6.7T, 6.8T, 6.9T, 7.0T, 7.1T, 7.2T, 7.3T, 7.4T, 7.5T, 7.6T, 7.7T, 7.8T, 7.9T, 8.0T, 8.1T, 8.2T, 8.3T, 8.4T, 8.5T, 8.6T, 8.7T, 8.8T, 8.9T, 9.0T, 9.1T, 9.2T, 9.3T, 9.4T, 9.5T, 9.6T, 9.7T, 9.8T, 9.9T, 10.0T, 10.1T, 10.2T, 10.3T, 10.4T, 10.5T, 10.6T, 10.7T, 10.8T, 10.9T, 11.0T, 11.1T, 11.2T, 11.3T, 11.4T, 11.5T, 11.6T, 11.7T, 11.8T, 11.9T, 12.0T, 12.1T, 12.2T, 12.3T, 12.4T, 12.5T, 12.6T, 12.7T, 12.8T, 12.9T, 13.0T, 13.1T, 13.2T, 13.3T, 13.4T, 13.5T, 13.6T, 13.7T, 13.8T, 13.9T, 14.0T, 14.1T, 14.2T, 14.3T, 14.4T, 14.5T, 14.6T, 14.7T, 14.8T, 14.9T, 15.0T, 15.1T, 15.2T, 15.3T, 15.4T, 15.5T, 15.6T, 15.7T, 15.8T, 15.9T, 16.0T, 16.1T, 16.2T, 16.3T, 16.4T, 16.5T, 16.6T, 16.7T, 16.8T, 16.9T, 17.0T, 17.1T, 17.2T, 17.3T, 17.4T, 17.5T, 17.6T, 17.7T, 17.8T, 17.9T, 18.0T, 18.1T, 18.2T, 18.3T, 18.4T, 18.5T, 18.6T, 18.7T, 18.8T, 18.9T, 19.0T, 19.1T, 19.2T, 19.3T, 19.4T, 19.5T, 19.6T, 19.7T, 19.8T, 19.9T, 20.0T, 20.1T, 20.2T, 20.3T, 20.4T, 20.5T, 20.6T, 20.7T, 20.8T, 20.9T, or more. Furthermore, the superconducting coils may be used in generating magnetic fields that are outside the range of 4T to 20T or that are within the range of 4T to 20T but that are not specifically listed herein.
In some implementations, such as the implementations shown in
In some implementations, the return yokes and shield may be replaced by, or augmented by, an active return system. An example active return system includes one or more active return coils that conduct current in a direction opposite to current through the main superconducting coils. In some example implementations, there is an active return coil for each superconducting main coil, e.g., two active return coils—one for each main superconducting coil. Each active return coil may also be a superconducting coil that surrounds the outside of a corresponding main superconducting coil concentrically.
By using an active return system, the relatively large ferromagnetic magnetic yokes 1214, 1215 can be replaced with magnetic pole pieces that are smaller and lighter. Accordingly, the size and weight of the synchrocyclotron can be reduced further without sacrificing performance. An example of an active return system that may be used is described in U.S. Pat. No. 8,791,656 entitled “Active Return System”, the contents of which are incorporated herein by reference.
At or near the output of the extraction channel of the particle accelerator, there may be one or more beam shaping elements, such as a scanning system and/or a scattering system. Components of these systems may be mounted on, or otherwise attached to, the nozzle for positioning relatively close to the patient during treatment. In some implementations, however, beam spreader(s) may be mounted closer to (e.g., on) the accelerator or the outer gantry itself (e.g., mounted to the outer gantry in the absence of an accelerator mounted there).
Referring to
In an example operation, scanning magnet 1324 is an example beam spreader, and is controllable in two dimensions (e.g., Cartesian XY dimensions) to position the particle beam in those two dimensions, and to move the particle beam across at least a part (e.g., a cross-section) of an irradiation target. Ion chamber 1325 detects the dosage of the beam and feeds-back that information to a control system to adjust beam movement. Energy degrader 1326 is controllable to move material (e.g., one or more individual plates) into, and out of, the path of the particle beam to change the energy of the particle beam and therefore the depth to which the particle beam will penetrate the irradiation target. In this way, the energy degrader can position the particle beam at a depth-wise layer of an irradiation target, e.g., to the layer. In some implementations, the energy degrader uses wedges or other types of structures instead of, or in addition to, plates. For example, energy degrader 1326 may be controllable to move material (e.g., one or more individual wedges) into, and out of, the path of the particle beam to change the energy of the particle beam and therefore the depth to which the particle beam will penetrate the irradiation target.
Referring back to
During operation, the magnitude(s) (e.g., value(s)) of the magnet current(s)) may be stored for each location at which a dose is delivered, along with the amount (e.g., intensity) of the dose. A computer system, which may be either on the accelerator or remote from the accelerator and which may include memory and one or more processing devices, may correlate the magnet current to coordinates within the radiation target, and those coordinates may be stored along with the amount of the dose. For example, the location may be identified by depth-wise layer number and Cartesian XY coordinates or by Cartesian XYZ coordinates (with the depth-wise layer corresponding to the Z coordinate). In some implementations, both the magnitude of the magnet current and the coordinate locations may be stored along with the dose at each location. The foregoing information may be stored in memory either on, or remote from, the accelerator. This information may be used during scanning to apply multiple doses of the same or of different amounts to the same locations to achieve target cumulative doses, including at areas of overlap between adjacent/sequential beam fields, as described herein.
In some implementations, ion chamber 1325 detects dosage (e.g., one or more individual doses) applied by the particle beam to positions on an irradiation target by detecting the numbers of ion pairs created within a gas caused by incident radiation. The numbers of ion pairs correspond to the dose provided by the particle beam. That information is fed-back to the computer system and stored in memory along with the time that the dose is provided. This information may be correlated to, and stored in association with, the location at which the dose was provided and/or the magnitude of the magnet current at that time, as described above.
Configurable collimator 1328 may be located down-beam of the scanning magnets and down-beam of the energy degrader, as shown in
One or more of the plates is movable into, or out of, the beam path to thereby affect the energy of the particle beam and, thus, the depth of penetration of the particle beam within the irradiation target. Plates are moved physically into, and out of, the path of the particle beam. For example, as shown in
Some components of the scanning system, including the configurable collimator, may be mounted on, or coupled to, a nozzle 1981 of the particle therapy system's inner gantry 1980 (see
As noted, the particle beam passes from the range modulator, through the configurable collimator, to the patient. Passage through air can cause the beam spot size to increase. The longer that the beam passes through air, the greater this spot size increase may be. Accordingly, in some implementations, it is advantageous to reduce the maximum distance that the beam can pass through the air. As explained above, in some examples, the components mounted on the nozzle closest to the patient (e.g., a collimator and energy degrader) may reduce the amount that the beam passes through the air. However, in some examples, because of their proximity to the patient, those components may be made relatively small. The size of those components is related to the treatable field size. That is, these smaller components may result in a relatively smaller beam field size.
In the example of
In the example of
Operation of the example particle therapy systems described herein, and operation of all or some component thereof, can be controlled (as appropriate), at least in part, using one or more computer program products, e.g., one or more computer programs tangibly embodied in one or more non-transitory machine-readable media, for execution by, or to control the operation of, one or more data processing apparatus, e.g., a programmable processor, a computer, multiple computers, and/or programmable logic components.
A computer program can be written in any form of programming language, including compiled or interpreted languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment. A computer program can be deployed to be executed on one computer or on multiple computers at one site or distributed across multiple sites and interconnected by a network.
Actions associated with implementing all or part of the operations of the example particle therapy systems described herein can be performed by one or more programmable processors executing one or more computer programs to perform the functions described herein. All or part of the operations can be implemented using special purpose logic circuitry, e.g., an FPGA (field programmable gate array) and/or an ASIC (application-specific integrated circuit).
Processors suitable for the execution of a computer program include, by way of example, both general and special purpose microprocessors, and any one or more processors of any kind of digital computer. Generally, a processor will receive instructions and data from a read-only storage area or a random access storage area or both. Elements of a computer (including a server) include one or more processors for executing instructions and one or more storage area devices for storing instructions and data. Generally, a computer will also include, or be operatively coupled to receive data from, or transfer data to, or both, one or more machine-readable storage media, such as mass PCBs for storing data, e.g., magnetic, magneto-optical disks, or optical disks. Non-transitory machine-readable storage media suitable for embodying computer program instructions and data include all forms of non-volatile storage area, including by way of example, semiconductor storage area devices, e.g., EPROM, EEPROM, and flash storage area devices; magnetic disks, e.g., internal hard disks or removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks.
Any “electrical connection” as used herein may imply a direct physical connection or a wired or wireless connection that includes intervening components but that nevertheless allows electrical signals to flow between connected components. Any “connection” involving electrical circuitry that allows signals to flow, unless stated otherwise, is an electrical connection and not necessarily a direct physical connection regardless of whether the word “electrical” is used to modify “connection”.
Any two more of the foregoing implementations may be used in an appropriate combination with an appropriate particle accelerator (e.g., a synchrocyclotron). Likewise, individual features of any two more of the foregoing implementations may be used in an appropriate combination. Elements may be left out of the processes, systems, apparatus, etc., described herein without adversely affecting their operation. Various separate elements may be combined into one or more individual elements to perform the functions described herein.
In some implementations, the synchrocyclotron used in the particle therapy system described herein may be a variable-energy synchrocyclotron. In some implementations, a variable-energy synchrocyclotron is configured to vary the energy of the output particle beam by varying the magnetic field in which the particle beam is accelerated. For example, the current may be set to any one of multiple values to produce a corresponding magnetic field. In an example implementation, one or more sets of superconducting coils receives variable electrical current to produce a variable magnetic field in the cavity. In some examples, one set of coils receives a fixed electrical current, while one or more other sets of coils receives a variable current so that the total current received by the coil sets varies. In some implementations, all sets of coils are superconducting. In some implementations, some sets of coils, such as the set for the fixed electrical current, are superconducting, while other sets of coils, such as the one or more sets for the variable current, are non-superconducting (e.g., copper) coils.
Generally, in a variable-energy synchrocyclotron, the magnitude of the magnetic field is scalable with the magnitude of the electrical current. Adjusting the total electric current of the coils in a predetermined range can generate a magnetic field that varies in a corresponding, predetermined range. In some examples, a continuous adjustment of the electrical current can lead to a continuous variation of the magnetic field and a continuous variation of the output beam energy. Alternatively, when the electrical current applied to the coils is adjusted in a non-continuous, step-wise manner, the magnetic field and the output beam energy also varies accordingly in a non-continuous (step-wise) manner. The scaling of the magnetic field to the current can allow the variation of the beam energy to be carried out relatively precisely, thus reducing the need for an energy degrader. In a variable-energy synchrocyclotron, the voltage source is controllable to sweep RF voltage over a different frequency ranges, with each different frequency range corresponding to each different energy at which the particles are output from the cavity. An example of a variable-energy synchrocyclotron that may be used in the particle therapy system is described in U.S. Patent Publication No. 2014/0371511 entitled “Particle Accelerator That Produces Charged Particles Having Variable Energies”, the contents of which are incorporated herein by reference. Linear motor-driven collimators may be used in a variable-energy synchrocyclotron system of the type described in U.S. Patent Publication No. 2014/037151.
In some implementations, a particle accelerator other than a synchrocyclotron may be used in the particle therapy system described herein. For example, a cyclotron, a synchrotron, a linear accelerator, or the like may be substituted for the synchrocyclotron described herein. Although a rotational gantry has been described (e.g., the outer gantry), the example particle therapy systems described herein are not limited to use with rotational gantries. Rather, a particle accelerator may be mounted, as appropriate, on any type of robotic or other controllable mechanism(s)—characterized herein also as types of gantries—to implement movement of the particle accelerator. For example, the particle accelerator may be mounted on or more robotic arms to implement rotational, pivotal, and/or translational movement of the accelerator relative to the patient. In some implementations, the particle accelerator may be mounted on a track, and movement along the track may be computer-controlled. In this configuration, rotational and/or translational and/or pivotal movement of the accelerator relative to the patient can also be achieved through appropriate computer control.
The example linear motors described may be used in conjunction with any appropriate features and systems described in U.S. Patent Publication No. 2017/0128746 (application Ser. No. 14/937,048) entitled “Adaptive Aperture”, which is incorporated herein by reference.
This application claims priority to U.S. Provisional Application No. 62/527,539, filed Jun. 30, 2017, the disclosure of which is incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
463291 | Dodson | Nov 1891 | A |
773508 | Leblanc | Oct 1904 | A |
2280606 | Roberts | Apr 1942 | A |
2492324 | Salisbury | Dec 1949 | A |
2615129 | Mcmillan | Oct 1952 | A |
2616042 | Ray | Oct 1952 | A |
2659000 | Salisbury | Nov 1953 | A |
2701304 | Dickinson | Feb 1955 | A |
2789222 | Martin et al. | Apr 1957 | A |
2958327 | Geissmann | Nov 1960 | A |
3024379 | Verster | Mar 1962 | A |
3175131 | Burleigh et al. | Mar 1965 | A |
3432721 | Naydan et al. | Mar 1969 | A |
3582650 | Avery | Jun 1971 | A |
3679899 | Dimeff | Jul 1972 | A |
3689847 | Verster | Sep 1972 | A |
3757118 | Hodge et al. | Sep 1973 | A |
3868522 | Bigham et al. | Feb 1975 | A |
3886367 | Castle, Jr. | May 1975 | A |
3925676 | Bigham et al. | Dec 1975 | A |
3955089 | McIntyre et al. | May 1976 | A |
3958327 | Marancik et al. | May 1976 | A |
3992625 | Schmidt et al. | Nov 1976 | A |
4038622 | Purcell | Jul 1977 | A |
4047068 | Ress et al. | Sep 1977 | A |
4112306 | Nunan | Sep 1978 | A |
4129784 | Tschunt et al. | Dec 1978 | A |
4139777 | Rautenbach | Feb 1979 | A |
4197510 | Szu | Apr 1980 | A |
4220866 | Taumann et al. | Sep 1980 | A |
4230129 | LeVeen | Oct 1980 | A |
4256966 | Heinz | Mar 1981 | A |
4293772 | Stieber | Oct 1981 | A |
4336505 | Meyer | Jun 1982 | A |
4342060 | Gibson | Jul 1982 | A |
4345210 | Tran | Aug 1982 | A |
4353033 | Karasawa | Oct 1982 | A |
4425506 | Brown et al. | Jan 1984 | A |
4490616 | Cipollina et al. | Dec 1984 | A |
4507614 | Prono et al. | Mar 1985 | A |
4507616 | Blosser et al. | Mar 1985 | A |
4589126 | Augustsson et al. | May 1986 | A |
4598208 | Brunelli et al. | Jul 1986 | A |
4628523 | Heflin | Dec 1986 | A |
4633125 | Blosser et al. | Dec 1986 | A |
4641057 | Blosser et al. | Feb 1987 | A |
4641104 | Blosser et al. | Feb 1987 | A |
4651007 | Perusek et al. | Mar 1987 | A |
4680565 | Jahnke | Jul 1987 | A |
4705955 | Mileikowsky | Nov 1987 | A |
4710722 | Jahnke | Dec 1987 | A |
4726046 | Nunan | Feb 1988 | A |
4734653 | Jahnke | Mar 1988 | A |
4736106 | Kashy et al. | Apr 1988 | A |
4736173 | Basil, Jr. et al. | Apr 1988 | A |
4737727 | Yamada et al. | Apr 1988 | A |
4739173 | Blosser et al. | Apr 1988 | A |
4745367 | Dustmann et al. | May 1988 | A |
4754147 | Maughan et al. | Jun 1988 | A |
4763483 | Olsen | Aug 1988 | A |
4767930 | Stieber et al. | Aug 1988 | A |
4769623 | Marsing et al. | Sep 1988 | A |
4771208 | Jongen et al. | Sep 1988 | A |
4783634 | Yamamoto et al. | Nov 1988 | A |
4808941 | Marsing | Feb 1989 | A |
4812658 | Koehler | Mar 1989 | A |
4843333 | Marsing et al. | Jun 1989 | A |
4845371 | Stieber | Jul 1989 | A |
4865284 | Gosis et al. | Sep 1989 | A |
4868843 | Nunan | Sep 1989 | A |
4868844 | Nunan | Sep 1989 | A |
4870287 | Cole et al. | Sep 1989 | A |
4880985 | Jones | Nov 1989 | A |
4894541 | Ono | Jan 1990 | A |
4896206 | Denham | Jan 1990 | A |
4902993 | Krevet | Feb 1990 | A |
4904949 | Wilson | Feb 1990 | A |
4905267 | Miller et al. | Feb 1990 | A |
4917344 | Prechter et al. | Apr 1990 | A |
4943781 | Wilson et al. | Jul 1990 | A |
4945478 | Merickel et al. | Jul 1990 | A |
4968915 | Wilson et al. | Nov 1990 | A |
4987309 | Klasen et al. | Jan 1991 | A |
4992744 | Fujita et al. | Feb 1991 | A |
4996496 | Kitamura et al. | Feb 1991 | A |
5006759 | Krispel | Apr 1991 | A |
5010562 | Hernandez et al. | Apr 1991 | A |
5012111 | Ueda | Apr 1991 | A |
5017789 | Young et al. | May 1991 | A |
5017882 | Finlan | May 1991 | A |
5036290 | Sonobe et al. | Jul 1991 | A |
5039057 | Prechter et al. | Aug 1991 | A |
5039867 | Nishihara et al. | Aug 1991 | A |
5046078 | Hernandez et al. | Sep 1991 | A |
5072123 | Johnsen | Dec 1991 | A |
5111042 | Sullivan et al. | May 1992 | A |
5111173 | Matsuda et al. | May 1992 | A |
5117194 | Nakanishi et al. | May 1992 | A |
5117212 | Yamamoto et al. | May 1992 | A |
5117829 | Miller et al. | Jun 1992 | A |
5144647 | Kikuchi | Sep 1992 | A |
5148032 | Hernandez | Sep 1992 | A |
5166531 | Huntzinger | Nov 1992 | A |
5189687 | Bova et al. | Feb 1993 | A |
5191706 | Cosden | Mar 1993 | A |
5240218 | Dye | Aug 1993 | A |
5260579 | Yasuda et al. | Nov 1993 | A |
5260581 | Lesyna et al. | Nov 1993 | A |
5278533 | Kawaguchi | Jan 1994 | A |
5285166 | Hiramoto et al. | Feb 1994 | A |
5317164 | Kurokawa | May 1994 | A |
5336891 | Crewe | Aug 1994 | A |
5341104 | Anton et al. | Aug 1994 | A |
5349198 | Takanaka | Sep 1994 | A |
5365742 | Boffito et al. | Nov 1994 | A |
5374913 | Pissantezky et al. | Dec 1994 | A |
5382914 | Hamm et al. | Jan 1995 | A |
5401973 | McKeown et al. | Mar 1995 | A |
5405235 | Lebre et al. | Apr 1995 | A |
5434420 | McKeown et al. | Jul 1995 | A |
5440133 | Moyers et al. | Aug 1995 | A |
5451794 | McKeown et al. | Sep 1995 | A |
5461773 | Kawaguchi | Oct 1995 | A |
5463291 | Carroll et al. | Oct 1995 | A |
5464411 | Schulte et al. | Nov 1995 | A |
5492922 | Palkowitz | Feb 1996 | A |
5511549 | Legg et al. | Apr 1996 | A |
5521469 | Laisne | May 1996 | A |
5538942 | Koyama et al. | Jul 1996 | A |
5549616 | Schulte et al. | Aug 1996 | A |
5561697 | Takafuji et al. | Oct 1996 | A |
5585642 | Britton et al. | Dec 1996 | A |
5633747 | Nikoonahad | May 1997 | A |
5635721 | Bardi et al. | Jun 1997 | A |
5668371 | Deasy et al. | Sep 1997 | A |
5672878 | Yao | Sep 1997 | A |
5691679 | Ackermann et al. | Nov 1997 | A |
5726448 | Smith et al. | Mar 1998 | A |
5727554 | Kalend et al. | Mar 1998 | A |
5730745 | Schulte et al. | Mar 1998 | A |
5748703 | Cosman | May 1998 | A |
5751781 | Brown et al. | May 1998 | A |
5764723 | Weinberger et al. | Jun 1998 | A |
5778047 | Mansfield et al. | Jul 1998 | A |
5783914 | Hiramoto et al. | Jul 1998 | A |
5784431 | Kalend et al. | Jul 1998 | A |
5797924 | Schulte et al. | Aug 1998 | A |
5811944 | Sampayan et al. | Sep 1998 | A |
5818058 | Nakanishi et al. | Oct 1998 | A |
5821705 | Caporaso et al. | Oct 1998 | A |
5825845 | Blair et al. | Oct 1998 | A |
5841237 | Alton | Nov 1998 | A |
5846043 | Spath | Dec 1998 | A |
5851182 | Sahadevan | Dec 1998 | A |
5866912 | Slater et al. | Feb 1999 | A |
5874811 | Finlan et al. | Feb 1999 | A |
5895926 | Britton et al. | Apr 1999 | A |
5920601 | Nigg et al. | Jul 1999 | A |
5929458 | Nemezawa et al. | Jul 1999 | A |
5963615 | Egley et al. | Oct 1999 | A |
5986274 | Akiyama et al. | Nov 1999 | A |
5993373 | Nonaka et al. | Nov 1999 | A |
6008499 | Hiramoto et al. | Dec 1999 | A |
6034377 | Pu | Mar 2000 | A |
6057655 | Jongen | May 2000 | A |
6061426 | Linders et al. | May 2000 | A |
6064807 | Arai et al. | May 2000 | A |
6066851 | Madono et al. | May 2000 | A |
6080992 | Nonaka et al. | Jun 2000 | A |
6087670 | Hiramoto et al. | Jul 2000 | A |
6087672 | Matsuda et al. | Jul 2000 | A |
6094760 | Nonaka et al. | Aug 2000 | A |
6118848 | Reiffel | Sep 2000 | A |
6140021 | Nakasuji et al. | Oct 2000 | A |
6144875 | Schweikard et al. | Nov 2000 | A |
6158708 | Egley et al. | Dec 2000 | A |
6207952 | Kan et al. | Mar 2001 | B1 |
6219403 | Nishihara | Apr 2001 | B1 |
6222905 | Yoda et al. | Apr 2001 | B1 |
6241671 | Ritter et al. | Jun 2001 | B1 |
6246066 | Yuehu | Jun 2001 | B1 |
6256591 | Yoda et al. | Jul 2001 | B1 |
6265837 | Akiyama et al. | Jul 2001 | B1 |
6268610 | Pu | Jul 2001 | B1 |
6278239 | Caporaso et al. | Aug 2001 | B1 |
6279579 | Riaziat et al. | Aug 2001 | B1 |
6307914 | Kunieda et al. | Oct 2001 | B1 |
6316776 | Hiramoto et al. | Nov 2001 | B1 |
6366021 | Meddaugh et al. | Apr 2002 | B1 |
6369585 | Yao | Apr 2002 | B2 |
6380545 | Yan | Apr 2002 | B1 |
6407505 | Bertsche | Jun 2002 | B1 |
6417634 | Bergstrom | Jul 2002 | B1 |
6433336 | Jongen et al. | Aug 2002 | B1 |
6433349 | Akiyama et al. | Aug 2002 | B2 |
6433494 | Kulish et al. | Aug 2002 | B1 |
6441569 | Janzow | Aug 2002 | B1 |
6443349 | Van Der Burg | Sep 2002 | B1 |
6459769 | Cosman | Oct 2002 | B1 |
6465957 | Whitham et al. | Oct 2002 | B1 |
6472834 | Hiramoto et al. | Oct 2002 | B2 |
6476403 | Dolinskii et al. | Nov 2002 | B1 |
6492922 | New | Dec 2002 | B1 |
6493424 | Whitham | Dec 2002 | B2 |
6498444 | Hanna et al. | Dec 2002 | B1 |
6501981 | Schweikard et al. | Dec 2002 | B1 |
6519316 | Collins | Feb 2003 | B1 |
6593696 | Ding et al. | Jul 2003 | B2 |
6594336 | Nishizawa et al. | Jul 2003 | B2 |
6600164 | Badura et al. | Jul 2003 | B1 |
6617598 | Matsuda | Sep 2003 | B1 |
6621889 | Mostafavi | Sep 2003 | B1 |
6630675 | Ghelmansarai | Oct 2003 | B2 |
6639234 | Badura et al. | Oct 2003 | B1 |
6646383 | Bertsche et al. | Nov 2003 | B2 |
6670618 | Hartmann et al. | Dec 2003 | B1 |
6683162 | Scheinberg et al. | Jan 2004 | B2 |
6683318 | Haberer et al. | Jan 2004 | B1 |
6683426 | Kleeven | Jan 2004 | B1 |
6693283 | Eickhoff et al. | Feb 2004 | B2 |
6710362 | Kraft et al. | Mar 2004 | B2 |
6713773 | Lyons et al. | Mar 2004 | B1 |
6713976 | Zumoto et al. | Mar 2004 | B1 |
6714620 | Caflisch et al. | Mar 2004 | B2 |
6717162 | Jongen | Apr 2004 | B1 |
6745072 | Badura et al. | Jun 2004 | B1 |
6757355 | Siochi | Jun 2004 | B1 |
6769806 | Moyers | Aug 2004 | B2 |
6774383 | Norimine et al. | Aug 2004 | B2 |
6777689 | Nelson | Aug 2004 | B2 |
6777700 | Yanagisawa et al. | Aug 2004 | B2 |
6780149 | Schulte | Aug 2004 | B1 |
6792078 | Kato et al. | Sep 2004 | B2 |
6799068 | Hartmann et al. | Sep 2004 | B1 |
6800866 | Amemiya et al. | Oct 2004 | B2 |
6803591 | Muramatsu et al. | Oct 2004 | B2 |
6813336 | Siochi | Nov 2004 | B1 |
6814694 | Pedroni | Nov 2004 | B1 |
6819743 | Kato et al. | Nov 2004 | B2 |
6822244 | Beloussov et al. | Nov 2004 | B2 |
6823045 | Kato et al. | Nov 2004 | B2 |
6853142 | Chistyakov | Feb 2005 | B2 |
6853703 | Svatos et al. | Feb 2005 | B2 |
6864770 | Nemoto et al. | Mar 2005 | B2 |
6865254 | Nafstadius | Mar 2005 | B2 |
6873123 | Marchand et al. | Mar 2005 | B2 |
6878951 | Ma | Apr 2005 | B2 |
6891177 | Kraft et al. | May 2005 | B1 |
6891924 | Yoda et al. | May 2005 | B1 |
6894300 | Reimoser et al. | May 2005 | B2 |
6897451 | Kaercher et al. | May 2005 | B2 |
6907105 | Otto | Jun 2005 | B2 |
6914396 | Symons et al. | Jul 2005 | B1 |
6931100 | Kato et al. | Aug 2005 | B2 |
6936832 | Norimine et al. | Aug 2005 | B2 |
6953943 | Yanagisawa et al. | Oct 2005 | B2 |
6965116 | Wagner et al. | Nov 2005 | B1 |
6969194 | Nafstadius | Nov 2005 | B1 |
6979832 | Yanagisawa et al. | Dec 2005 | B2 |
6984835 | Harada | Jan 2006 | B2 |
6992312 | Yanagisawa et al. | Jan 2006 | B2 |
6993112 | Hesse | Jan 2006 | B2 |
6998604 | Nishizawa et al. | Feb 2006 | B2 |
7008105 | Amann et al. | Mar 2006 | B2 |
7011447 | Moyers | Mar 2006 | B2 |
7012267 | Moriyama et al. | Mar 2006 | B2 |
7014361 | Ein-Gal | Mar 2006 | B1 |
7026636 | Yanagisawa et al. | Apr 2006 | B2 |
7038403 | Mastrangeli et al. | May 2006 | B2 |
7041479 | Swartz et al. | May 2006 | B2 |
7045781 | Adamec et al. | May 2006 | B2 |
7049613 | Yanagisawa et al. | May 2006 | B2 |
7053389 | Yanagisawa et al. | May 2006 | B2 |
7054801 | Sakamoto et al. | May 2006 | B2 |
7060997 | Norimine et al. | Jun 2006 | B2 |
7071479 | Yanagisawa et al. | Jul 2006 | B2 |
7073508 | Moyers | Jul 2006 | B2 |
7081619 | Bashkirov et al. | Jul 2006 | B2 |
7084410 | Beloussov et al. | Aug 2006 | B2 |
7091478 | Haberer | Aug 2006 | B2 |
7095823 | Topolnjak et al. | Aug 2006 | B2 |
7102144 | Matsuda et al. | Sep 2006 | B2 |
7122811 | Matsuda et al. | Oct 2006 | B2 |
7122966 | Norling et al. | Oct 2006 | B2 |
7122978 | Nakanishi et al. | Oct 2006 | B2 |
7135678 | Wang et al. | Nov 2006 | B2 |
7138771 | Bechthold et al. | Nov 2006 | B2 |
7154107 | Yanagisawa et al. | Dec 2006 | B2 |
7154108 | Tadokoro et al. | Dec 2006 | B2 |
7154991 | Earnst et al. | Dec 2006 | B2 |
7162005 | Bjorkholm | Jan 2007 | B2 |
7173264 | Moriyama et al. | Feb 2007 | B2 |
7173265 | Miller et al. | Feb 2007 | B2 |
7173385 | Caporaso et al. | Feb 2007 | B2 |
7186991 | Kato et al. | Mar 2007 | B2 |
7193227 | Hiramoto et al. | Mar 2007 | B2 |
7199382 | Rigney et al. | Apr 2007 | B2 |
7208748 | Sliski et al. | Apr 2007 | B2 |
7212608 | Nagamine et al. | May 2007 | B2 |
7212609 | Nagamine et al. | May 2007 | B2 |
7221733 | Takai et al. | May 2007 | B1 |
7227161 | Matsuda et al. | Jun 2007 | B2 |
7247869 | Tadokoro et al. | Jul 2007 | B2 |
7257191 | Sommer | Aug 2007 | B2 |
7259529 | Tanaka | Aug 2007 | B2 |
7262424 | Moriyama et al. | Aug 2007 | B2 |
7262565 | Fujisawa | Aug 2007 | B2 |
7268358 | Ma et al. | Sep 2007 | B2 |
7274018 | Adamec et al. | Sep 2007 | B2 |
7280633 | Cheng et al. | Oct 2007 | B2 |
7295649 | Johnsen | Nov 2007 | B2 |
7297967 | Yanagisawa et al. | Nov 2007 | B2 |
7301162 | Matsuda et al. | Nov 2007 | B2 |
7307264 | Brusasco et al. | Dec 2007 | B2 |
7317192 | Ma | Jan 2008 | B2 |
7318805 | Schweikard et al. | Jan 2008 | B2 |
7319231 | Moriyama et al. | Jan 2008 | B2 |
7319336 | Baur et al. | Jan 2008 | B2 |
7331713 | Moyers | Feb 2008 | B2 |
7332880 | Ina et al. | Feb 2008 | B2 |
7345291 | Kats | Mar 2008 | B2 |
7345292 | Moriyama et al. | Mar 2008 | B2 |
7348557 | Armit | Mar 2008 | B2 |
7348579 | Pedroni | Mar 2008 | B2 |
7351988 | Naumann et al. | Apr 2008 | B2 |
7355189 | Yanagisawa et al. | Apr 2008 | B2 |
7368740 | Beloussov et al. | May 2008 | B2 |
7372053 | Yamashita et al. | May 2008 | B2 |
7378672 | Harada | May 2008 | B2 |
7381979 | Yamashita et al. | Jun 2008 | B2 |
7386099 | Kasper et al. | Jun 2008 | B1 |
7397054 | Natori et al. | Jul 2008 | B2 |
7397901 | Johnsen | Jul 2008 | B1 |
7398309 | Baumann et al. | Jul 2008 | B2 |
7402822 | Guertin et al. | Jul 2008 | B2 |
7402823 | Guertin et al. | Jul 2008 | B2 |
7402824 | Guertin et al. | Jul 2008 | B2 |
7402963 | Sliski et al. | Jul 2008 | B2 |
7405407 | Hiramoto et al. | Jul 2008 | B2 |
7425717 | Matsuda et al. | Sep 2008 | B2 |
7432516 | Peggs et al. | Oct 2008 | B2 |
7439528 | Nishiuchi et al. | Oct 2008 | B2 |
7446328 | Rigney et al. | Nov 2008 | B2 |
7446490 | Jongen et al. | Nov 2008 | B2 |
7449701 | Fujimaki et al. | Nov 2008 | B2 |
7453076 | Welch et al. | Nov 2008 | B2 |
7465944 | Ueno et al. | Dec 2008 | B2 |
7466085 | Nutt | Dec 2008 | B2 |
7468506 | Rogers et al. | Dec 2008 | B2 |
7473913 | Hermann et al. | Jan 2009 | B2 |
7476867 | Fritsch et al. | Jan 2009 | B2 |
7476883 | Nutt | Jan 2009 | B2 |
7482606 | Groezinger et al. | Jan 2009 | B2 |
7492556 | Atkins et al. | Feb 2009 | B2 |
7507975 | Mohr | Mar 2009 | B2 |
7525104 | Harada | Apr 2009 | B2 |
7531818 | Brahme | May 2009 | B2 |
7541905 | Antaya | Jun 2009 | B2 |
7547901 | Guertin et al. | Jun 2009 | B2 |
7554096 | Ward et al. | Jun 2009 | B2 |
7554097 | Ward et al. | Jun 2009 | B2 |
7554275 | Amaldi | Jun 2009 | B2 |
7555103 | Johnsen | Jun 2009 | B2 |
7557358 | Ward et al. | Jul 2009 | B2 |
7557359 | Ward et al. | Jul 2009 | B2 |
7557360 | Ward et al. | Jul 2009 | B2 |
7557361 | Ward et al. | Jul 2009 | B2 |
7560698 | Rietzel | Jul 2009 | B2 |
7560715 | Pedroni | Jul 2009 | B2 |
7560717 | Matsuda et al. | Jul 2009 | B2 |
7567694 | Lu et al. | Jul 2009 | B2 |
7574251 | Lu et al. | Aug 2009 | B2 |
7576499 | Caporaso et al. | Aug 2009 | B2 |
7579603 | Birgy et al. | Aug 2009 | B2 |
7579610 | Grozinger et al. | Aug 2009 | B2 |
7582866 | Furuhashi et al. | Sep 2009 | B2 |
7582885 | Katagiri et al. | Sep 2009 | B2 |
7582886 | Trbojevic | Sep 2009 | B2 |
7586112 | Chiba et al. | Sep 2009 | B2 |
7598497 | Yamamoto et al. | Oct 2009 | B2 |
7609009 | Tanaka et al. | Oct 2009 | B2 |
7609809 | Kapatoes et al. | Oct 2009 | B2 |
7609811 | Siljamaki et al. | Oct 2009 | B1 |
7615942 | Sanders et al. | Nov 2009 | B2 |
7626347 | Sliski et al. | Dec 2009 | B2 |
7629598 | Harada | Dec 2009 | B2 |
7629599 | Hashimoto | Dec 2009 | B2 |
7639853 | Olivera et al. | Dec 2009 | B2 |
7639854 | Schnarr et al. | Dec 2009 | B2 |
7643661 | Ruchala et al. | Jan 2010 | B2 |
7656258 | Antaya et al. | Feb 2010 | B1 |
7659521 | Pedroni | Feb 2010 | B2 |
7659528 | Uematsu | Feb 2010 | B2 |
7668291 | Nord et al. | Feb 2010 | B2 |
7672429 | Urano et al. | Mar 2010 | B2 |
7679049 | Rietzel | Mar 2010 | B2 |
7679073 | Urano et al. | Mar 2010 | B2 |
7682078 | Rietzel | Mar 2010 | B2 |
7692166 | Muraki et al. | Apr 2010 | B2 |
7692168 | Moriyama et al. | Apr 2010 | B2 |
7696499 | Miller et al. | Apr 2010 | B2 |
7696847 | Antaya | Apr 2010 | B2 |
7701677 | Schultz et al. | Apr 2010 | B2 |
7709818 | Matsuda et al. | May 2010 | B2 |
7710051 | Caporaso et al. | May 2010 | B2 |
7718982 | Sliski et al. | May 2010 | B2 |
7723036 | Racila et al. | May 2010 | B2 |
7728311 | Gall | Jun 2010 | B2 |
7746978 | Cheng et al. | Jun 2010 | B2 |
7755068 | Ma et al. | Jul 2010 | B2 |
7755305 | Umezawa et al. | Jul 2010 | B2 |
7759642 | Nir | Jul 2010 | B2 |
7763867 | Birgy et al. | Jul 2010 | B2 |
7763873 | Flynn et al. | Jul 2010 | B2 |
7767988 | Kaiser et al. | Aug 2010 | B2 |
7770231 | Prater et al. | Aug 2010 | B2 |
7772577 | Saito et al. | Aug 2010 | B2 |
7773723 | Nord et al. | Aug 2010 | B2 |
7773788 | Lu et al. | Aug 2010 | B2 |
7778488 | Nord et al. | Aug 2010 | B2 |
7783010 | Clayton | Aug 2010 | B2 |
7784124 | Long et al. | Aug 2010 | B2 |
7784127 | Kuro et al. | Aug 2010 | B2 |
7786433 | Gunzert-Marx et al. | Aug 2010 | B2 |
7786451 | Ward et al. | Aug 2010 | B2 |
7786452 | Ward et al. | Aug 2010 | B2 |
7789560 | Moyers | Sep 2010 | B2 |
7791051 | Beloussov et al. | Sep 2010 | B2 |
7796731 | Nord et al. | Sep 2010 | B2 |
7801269 | Cravens et al. | Sep 2010 | B2 |
7801270 | Nord et al. | Sep 2010 | B2 |
7801988 | Baumann et al. | Sep 2010 | B2 |
7807982 | Nishiuchi et al. | Oct 2010 | B2 |
7809107 | Nord et al. | Oct 2010 | B2 |
7812319 | Diehl et al. | Oct 2010 | B2 |
7812326 | Grozinger et al. | Oct 2010 | B2 |
7816657 | Hansmann et al. | Oct 2010 | B2 |
7817778 | Nord et al. | Oct 2010 | B2 |
7817836 | Chao et al. | Oct 2010 | B2 |
7818045 | Rietzel | Oct 2010 | B2 |
7825388 | Nihongi et al. | Nov 2010 | B2 |
7826593 | Svensson et al. | Nov 2010 | B2 |
7834334 | Grozinger et al. | Nov 2010 | B2 |
7834336 | Boeh et al. | Nov 2010 | B2 |
7835494 | Nord et al. | Nov 2010 | B2 |
7835502 | Spence et al. | Nov 2010 | B2 |
7839972 | Ruchala et al. | Nov 2010 | B2 |
7839973 | Nord et al. | Nov 2010 | B2 |
7848488 | Mansfield | Dec 2010 | B2 |
7857756 | Warren et al. | Dec 2010 | B2 |
7858592 | Shames et al. | Dec 2010 | B2 |
7860216 | Jongen et al. | Dec 2010 | B2 |
7860550 | Saracen et al. | Dec 2010 | B2 |
7868301 | Diehl | Jan 2011 | B2 |
7875846 | Gunzert-Marx et al. | Jan 2011 | B2 |
7875861 | Huttenberger et al. | Jan 2011 | B2 |
7875868 | Moriyama et al. | Jan 2011 | B2 |
7881431 | Aoi et al. | Feb 2011 | B2 |
7894574 | Nord et al. | Feb 2011 | B1 |
7903781 | Foland et al. | Mar 2011 | B2 |
7906769 | Blasche et al. | Mar 2011 | B2 |
7907987 | Dempsey | Mar 2011 | B2 |
7914734 | Livingston | Mar 2011 | B2 |
7919765 | Timmer | Apr 2011 | B2 |
7920040 | Antaya et al. | Apr 2011 | B2 |
7920675 | Lomax et al. | Apr 2011 | B2 |
7928415 | Bert et al. | Apr 2011 | B2 |
7934869 | Ivanov et al. | May 2011 | B2 |
7939809 | Balakin | May 2011 | B2 |
7940881 | Jongen et al. | May 2011 | B2 |
7940894 | Balakin | May 2011 | B2 |
7943913 | Balakin | May 2011 | B2 |
7947969 | Pu | May 2011 | B2 |
7949096 | Cheng et al. | May 2011 | B2 |
7950587 | Henson et al. | May 2011 | B2 |
7953205 | Balakin | May 2011 | B2 |
7957508 | Brooks et al. | Jun 2011 | B2 |
7960710 | Kruip et al. | Jun 2011 | B2 |
7961844 | Takeda et al. | Jun 2011 | B2 |
7977648 | Westerly et al. | Jul 2011 | B2 |
7977656 | Fujimaki et al. | Jul 2011 | B2 |
7977657 | Flynn et al. | Jul 2011 | B2 |
7982198 | Nishiuchi et al. | Jul 2011 | B2 |
7982416 | Tanaka et al. | Jul 2011 | B2 |
7984715 | Moyers | Jul 2011 | B2 |
7986768 | Nord et al. | Jul 2011 | B2 |
7987053 | Schaffner | Jul 2011 | B2 |
7989785 | Emhofer et al. | Aug 2011 | B2 |
7990524 | Jureller et al. | Aug 2011 | B2 |
7997553 | Sloan et al. | Aug 2011 | B2 |
8002466 | Von Neubeck et al. | Aug 2011 | B2 |
8003964 | Stark et al. | Aug 2011 | B2 |
8009803 | Nord et al. | Aug 2011 | B2 |
8009804 | Siljamaki et al. | Aug 2011 | B2 |
8016336 | Messinger et al. | Sep 2011 | B2 |
8039822 | Rietzel | Oct 2011 | B2 |
8041006 | Boyden et al. | Oct 2011 | B2 |
8044364 | Yamamoto | Oct 2011 | B2 |
8045679 | Balakin | Oct 2011 | B2 |
8049187 | Tachikawa | Nov 2011 | B2 |
8053508 | Korkut et al. | Nov 2011 | B2 |
8053739 | Rietzel | Nov 2011 | B2 |
8053745 | Moore | Nov 2011 | B2 |
8053746 | Timmer et al. | Nov 2011 | B2 |
8063381 | Tsoupas et al. | Nov 2011 | B2 |
8067748 | Balakin | Nov 2011 | B2 |
8069675 | Radovinsky et al. | Dec 2011 | B2 |
8071966 | Kaiser et al. | Dec 2011 | B2 |
8080801 | Safai | Dec 2011 | B2 |
8085899 | Nord et al. | Dec 2011 | B2 |
8089054 | Balakin | Jan 2012 | B2 |
8090074 | Filiberti et al. | Jan 2012 | B2 |
8093564 | Balakin | Jan 2012 | B2 |
8093568 | Mackie et al. | Jan 2012 | B2 |
8111125 | Antaya et al. | Feb 2012 | B2 |
8129694 | Balakin | Mar 2012 | B2 |
8129699 | Balakin | Mar 2012 | B2 |
8144832 | Balakin | Mar 2012 | B2 |
8153989 | Tachikawa et al. | Apr 2012 | B2 |
8154001 | Flynn et al. | Apr 2012 | B2 |
8163709 | Kodym et al. | Apr 2012 | B2 |
8173981 | Trbojevic | May 2012 | B2 |
8178859 | Balakin | May 2012 | B2 |
8183541 | Wilkens et al. | May 2012 | B2 |
8188688 | Balakin | May 2012 | B2 |
8189889 | Pearlstein et al. | May 2012 | B2 |
8190233 | Dempsey | May 2012 | B2 |
8198607 | Balakin | Jun 2012 | B2 |
8207656 | Baumgartner et al. | Jun 2012 | B2 |
8222613 | Tajiri et al. | Jul 2012 | B2 |
8227768 | Smick et al. | Jul 2012 | B2 |
8229072 | Balakin | Jul 2012 | B2 |
8232536 | Harada | Jul 2012 | B2 |
8238513 | Ma | Aug 2012 | B2 |
8253121 | Gnutzmann et al. | Aug 2012 | B2 |
8254521 | Brooks et al. | Aug 2012 | B2 |
8263954 | Iwata | Sep 2012 | B2 |
8283645 | Guneysel | Oct 2012 | B2 |
8288742 | Balakin | Oct 2012 | B2 |
8291717 | Radovinsky et al. | Oct 2012 | B2 |
8294127 | Tachibana | Oct 2012 | B2 |
8304725 | Komuro et al. | Nov 2012 | B2 |
8304750 | Preikszas et al. | Nov 2012 | B2 |
8309941 | Balakin | Nov 2012 | B2 |
8330132 | Guertin et al. | Dec 2012 | B2 |
8334520 | Otaka et al. | Dec 2012 | B2 |
8335397 | Takane et al. | Dec 2012 | B2 |
8344340 | Gall et al. | Jan 2013 | B2 |
8350214 | Otaki et al. | Jan 2013 | B2 |
8351571 | Brinks et al. | Jan 2013 | B2 |
8354656 | Beloussov et al. | Jan 2013 | B2 |
8368038 | Balakin | Feb 2013 | B2 |
8368043 | Havelange et al. | Feb 2013 | B2 |
8373143 | Balakin | Feb 2013 | B2 |
8373145 | Balakin | Feb 2013 | B2 |
8373146 | Balakin | Feb 2013 | B2 |
8374314 | Balakin | Feb 2013 | B2 |
8378299 | Frosien | Feb 2013 | B2 |
8378311 | Balakin | Feb 2013 | B2 |
8378312 | Gordon et al. | Feb 2013 | B1 |
8378321 | Balakin | Feb 2013 | B2 |
8382943 | Clark | Feb 2013 | B2 |
8384053 | Balakin | Feb 2013 | B2 |
8389949 | Harada et al. | Mar 2013 | B2 |
8399866 | Balakin | Mar 2013 | B2 |
8405042 | Honda et al. | Mar 2013 | B2 |
8405056 | Amaldi et al. | Mar 2013 | B2 |
8415643 | Balakin | Apr 2013 | B2 |
8416918 | Nord et al. | Apr 2013 | B2 |
8421041 | Balakin | Apr 2013 | B2 |
8426833 | Trbojevic | Apr 2013 | B2 |
8436323 | Iseki et al. | May 2013 | B2 |
8436325 | Noda et al. | May 2013 | B2 |
8436327 | Balakin | May 2013 | B2 |
8440987 | Stephani et al. | May 2013 | B2 |
8445872 | Behrens et al. | May 2013 | B2 |
8459714 | Pomper et al. | Jun 2013 | B2 |
8461559 | Lomax | Jun 2013 | B2 |
8466441 | Iwata et al. | Jun 2013 | B2 |
8472583 | Star-Lack et al. | Jun 2013 | B2 |
8481951 | Jongen et al. | Jul 2013 | B2 |
8483357 | Siljamaki et al. | Jul 2013 | B2 |
8487278 | Balakin | Jul 2013 | B2 |
8487282 | Iseki et al. | Jul 2013 | B2 |
8507195 | Richer et al. | Aug 2013 | B2 |
8519365 | Balakin | Aug 2013 | B2 |
8525419 | Smith et al. | Sep 2013 | B2 |
8525447 | Antaya | Sep 2013 | B2 |
8525448 | Tanaka et al. | Sep 2013 | B2 |
8536548 | Otani et al. | Sep 2013 | B2 |
8541762 | Claereboudt et al. | Sep 2013 | B2 |
8546769 | Uno | Oct 2013 | B2 |
8552406 | Phaneuf et al. | Oct 2013 | B2 |
8552408 | Hanawa et al. | Oct 2013 | B2 |
8558461 | Poehlmann-Martins et al. | Oct 2013 | B2 |
8558485 | Antaya | Oct 2013 | B2 |
8565377 | Robar et al. | Oct 2013 | B2 |
8569717 | Balakin | Oct 2013 | B2 |
8575563 | Cameron et al. | Nov 2013 | B2 |
8575564 | Iwata | Nov 2013 | B2 |
8575579 | Moskvin et al. | Nov 2013 | B2 |
8581215 | Balakin | Nov 2013 | B2 |
8581218 | Fujimoto et al. | Nov 2013 | B2 |
8581523 | Gall et al. | Nov 2013 | B2 |
8581525 | Antaya et al. | Nov 2013 | B2 |
8586948 | Pu et al. | Nov 2013 | B2 |
8598543 | Balakin | Dec 2013 | B2 |
8601116 | Baumann et al. | Dec 2013 | B2 |
8604454 | Guertin et al. | Dec 2013 | B2 |
8613694 | Walsh | Dec 2013 | B2 |
8614554 | Balakin | Dec 2013 | B2 |
8614612 | Antaya et al. | Dec 2013 | B2 |
8618519 | Ueda | Dec 2013 | B2 |
8618521 | Loo et al. | Dec 2013 | B2 |
8619242 | Suzuki | Dec 2013 | B2 |
8624528 | Balakin | Jan 2014 | B2 |
8625739 | Balakin | Jan 2014 | B2 |
8627822 | Balakin | Jan 2014 | B2 |
8632448 | Schulte et al. | Jan 2014 | B1 |
8633160 | Belmares et al. | Jan 2014 | B2 |
8637818 | Balakin | Jan 2014 | B2 |
8637839 | Brauer | Jan 2014 | B2 |
8642978 | Balakin | Feb 2014 | B2 |
8643314 | Touchi | Feb 2014 | B2 |
8644571 | Schulte et al. | Feb 2014 | B1 |
8653314 | Pelati et al. | Feb 2014 | B2 |
8653473 | Yajima | Feb 2014 | B2 |
8657354 | Pomper et al. | Feb 2014 | B2 |
8657743 | Rietzel et al. | Feb 2014 | B2 |
8688197 | Balakin | Apr 2014 | B2 |
8702578 | Fahrig et al. | Apr 2014 | B2 |
8710462 | Balakin | Apr 2014 | B2 |
8712011 | Robar et al. | Apr 2014 | B2 |
8716663 | Brusasco et al. | May 2014 | B2 |
8718231 | Balakin | May 2014 | B2 |
8735848 | Asaba | May 2014 | B2 |
8748852 | Jongen | Jun 2014 | B2 |
8750453 | Cheng et al. | Jun 2014 | B2 |
8754386 | Iwata | Jun 2014 | B2 |
8766217 | Balakin | Jul 2014 | B2 |
8766218 | Jongen | Jul 2014 | B2 |
8771754 | Hallahan | Jul 2014 | B2 |
8791435 | Balakin | Jul 2014 | B2 |
8791656 | Zwart et al. | Jul 2014 | B1 |
8796648 | Fujimoto et al. | Aug 2014 | B2 |
8822965 | Asaba | Sep 2014 | B2 |
8835885 | Ogasawara | Sep 2014 | B2 |
8847179 | Fujitaka et al. | Sep 2014 | B2 |
8859264 | Bert et al. | Oct 2014 | B2 |
8866109 | Sasai | Oct 2014 | B2 |
8890097 | Iwata | Nov 2014 | B2 |
8896239 | Balakin | Nov 2014 | B2 |
8897857 | Tome et al. | Nov 2014 | B2 |
8901509 | Balakin | Dec 2014 | B2 |
8901520 | Tachibana et al. | Dec 2014 | B2 |
8907309 | Spotts | Dec 2014 | B2 |
8907311 | Gall et al. | Dec 2014 | B2 |
8907594 | Begg et al. | Dec 2014 | B2 |
8916838 | Claereboudt et al. | Dec 2014 | B2 |
8916841 | Totake et al. | Dec 2014 | B2 |
8916843 | Gall et al. | Dec 2014 | B2 |
8927946 | Behrens et al. | Jan 2015 | B2 |
8927950 | Gall et al. | Jan 2015 | B2 |
8933650 | O'Neal, III et al. | Jan 2015 | B2 |
8941083 | Stark et al. | Jan 2015 | B2 |
8941084 | Balakin | Jan 2015 | B2 |
8941086 | Yajima | Jan 2015 | B2 |
8947021 | Tsutsui | Feb 2015 | B2 |
8948341 | Beckman | Feb 2015 | B2 |
8952343 | Stephani et al. | Feb 2015 | B2 |
8952634 | Sliski et al. | Feb 2015 | B2 |
8957396 | Balakin | Feb 2015 | B2 |
8963111 | Claereboudt et al. | Feb 2015 | B2 |
8963112 | Balakin | Feb 2015 | B1 |
8964936 | Brooks et al. | Feb 2015 | B2 |
8969834 | Balakin | Mar 2015 | B2 |
8970137 | Gall et al. | Mar 2015 | B2 |
8971363 | Levecq et al. | Mar 2015 | B2 |
8975600 | Balakin | Mar 2015 | B2 |
8975602 | Huber et al. | Mar 2015 | B2 |
8975836 | Bromberg et al. | Mar 2015 | B2 |
8986186 | Zhang et al. | Mar 2015 | B2 |
8993522 | Vidyasagar et al. | Mar 2015 | B2 |
9006693 | Sasai | Apr 2015 | B2 |
9007740 | Touchi | Apr 2015 | B2 |
9012832 | Bert et al. | Apr 2015 | B2 |
9012866 | Benna et al. | Apr 2015 | B2 |
9012873 | Fujimoto et al. | Apr 2015 | B2 |
9018601 | Balakin | Apr 2015 | B2 |
9018603 | Loo et al. | Apr 2015 | B2 |
9024256 | Ruan et al. | May 2015 | B2 |
9029760 | Beddar et al. | May 2015 | B2 |
9044600 | Balakin | Jun 2015 | B2 |
9056199 | Balakin | Jun 2015 | B2 |
9058910 | Balakin | Jun 2015 | B2 |
9060998 | Stockfleth | Jun 2015 | B2 |
9061142 | Vilsmeier | Jun 2015 | B2 |
9061143 | Sasai et al. | Jun 2015 | B2 |
9084887 | Schulte et al. | Jul 2015 | B2 |
9084890 | Iwata | Jul 2015 | B2 |
9089696 | Verhaegen et al. | Jul 2015 | B2 |
9093209 | Jongen | Jul 2015 | B2 |
9095040 | Balakin | Jul 2015 | B2 |
9108050 | Bula et al. | Aug 2015 | B2 |
9114253 | Dempsey | Aug 2015 | B2 |
9142385 | Iwanaga | Sep 2015 | B1 |
9155186 | Zwart et al. | Oct 2015 | B2 |
9155908 | Meltsner et al. | Oct 2015 | B2 |
9185789 | Zwart et al. | Nov 2015 | B2 |
9186525 | Prieels et al. | Nov 2015 | B2 |
9188685 | Takayanagi et al. | Nov 2015 | B2 |
9196082 | Pearlstein et al. | Nov 2015 | B2 |
9220920 | Schulte et al. | Dec 2015 | B2 |
9220923 | Yajima et al. | Dec 2015 | B2 |
9237640 | Abs et al. | Jan 2016 | B2 |
9237642 | Kleeven | Jan 2016 | B2 |
9245336 | Mallya et al. | Jan 2016 | B2 |
9254396 | Mihaylov | Feb 2016 | B2 |
9259155 | Bharat et al. | Feb 2016 | B2 |
9271385 | Verbruggen et al. | Feb 2016 | B2 |
9283406 | Prieels | Mar 2016 | B2 |
9283407 | Benna et al. | Mar 2016 | B2 |
9289140 | Ross et al. | Mar 2016 | B2 |
9289624 | Jongen | Mar 2016 | B2 |
9297912 | Campbell et al. | Mar 2016 | B2 |
9301384 | Zwart et al. | Mar 2016 | B2 |
9302121 | Totake et al. | Apr 2016 | B2 |
9305742 | Aptaker et al. | Apr 2016 | B2 |
9324468 | Mansfield et al. | Apr 2016 | B2 |
9355784 | Abs | May 2016 | B2 |
9364688 | Pausch et al. | Jun 2016 | B2 |
9370089 | Ungaro et al. | Jun 2016 | B2 |
9381379 | Beckman | Jul 2016 | B2 |
9393443 | Fujimoto et al. | Jul 2016 | B2 |
9417302 | Kuhn | Aug 2016 | B2 |
9451688 | Jongen | Sep 2016 | B2 |
9451689 | Tsutsui | Sep 2016 | B2 |
9452300 | Anferov | Sep 2016 | B2 |
9452301 | Gall et al. | Sep 2016 | B2 |
9468608 | Lin et al. | Oct 2016 | B2 |
9492684 | Takayanagi et al. | Nov 2016 | B2 |
9776017 | Flynn et al. | Oct 2017 | B2 |
9962560 | Zwart et al. | May 2018 | B2 |
20010022502 | Akiyama et al. | Sep 2001 | A1 |
20020058007 | Scheinberg et al. | May 2002 | A1 |
20020101959 | Kato et al. | Aug 2002 | A1 |
20020172317 | Maksimchuk et al. | Nov 2002 | A1 |
20030048080 | Amemiya et al. | Mar 2003 | A1 |
20030125622 | Schweikard et al. | Jul 2003 | A1 |
20030136924 | Kraft et al. | Jul 2003 | A1 |
20030152197 | Moyers | Aug 2003 | A1 |
20030163015 | Yanagisawa et al. | Aug 2003 | A1 |
20030183779 | Norimine et al. | Oct 2003 | A1 |
20030234369 | Glukhoy | Dec 2003 | A1 |
20040000650 | Yanagisawa et al. | Jan 2004 | A1 |
20040017888 | Seppi et al. | Jan 2004 | A1 |
20040056212 | Yanagisawa et al. | Mar 2004 | A1 |
20040061077 | Muramatsu et al. | Apr 2004 | A1 |
20040061078 | Muramatsu et al. | Apr 2004 | A1 |
20040085023 | Chistyakov | May 2004 | A1 |
20040098445 | Baumann et al. | May 2004 | A1 |
20040111134 | Muramatsu et al. | Jun 2004 | A1 |
20040118081 | Reimoser et al. | Jun 2004 | A1 |
20040149934 | Yanagisawa et al. | Aug 2004 | A1 |
20040155206 | Marchand et al. | Aug 2004 | A1 |
20040159795 | Kaercher et al. | Aug 2004 | A1 |
20040164254 | Beloussov et al. | Aug 2004 | A1 |
20040173763 | Moriyama et al. | Sep 2004 | A1 |
20040174958 | Moriyama et al. | Sep 2004 | A1 |
20040183033 | Moriyama et al. | Sep 2004 | A1 |
20040183035 | Yanagisawa et al. | Sep 2004 | A1 |
20040190680 | Chang | Sep 2004 | A1 |
20040200982 | Moriyama et al. | Oct 2004 | A1 |
20040200983 | Fujimaki et al. | Oct 2004 | A1 |
20040213381 | Harada | Oct 2004 | A1 |
20040227104 | Matsuda et al. | Nov 2004 | A1 |
20040232356 | Norimine et al. | Nov 2004 | A1 |
20040240626 | Moyers | Dec 2004 | A1 |
20050008123 | Topolnjak et al. | Jan 2005 | A1 |
20050029472 | Ueno et al. | Feb 2005 | A1 |
20050051740 | Yanagisawa et al. | Mar 2005 | A1 |
20050058245 | Ein-Gal | Mar 2005 | A1 |
20050072940 | Beloussov et al. | Apr 2005 | A1 |
20050079235 | Stockfleth | Apr 2005 | A1 |
20050087700 | Tadokoro et al. | Apr 2005 | A1 |
20050089141 | Brown | Apr 2005 | A1 |
20050099145 | Nishiuchi et al. | May 2005 | A1 |
20050113327 | Roiz et al. | May 2005 | A1 |
20050127306 | Yanagisawa et al. | Jun 2005 | A1 |
20050139787 | Chiba et al. | Jun 2005 | A1 |
20050161618 | Pedroni | Jul 2005 | A1 |
20050167616 | Yanagisawa et al. | Aug 2005 | A1 |
20050184686 | Caporaso et al. | Aug 2005 | A1 |
20050186179 | Harats et al. | Aug 2005 | A1 |
20050205806 | Tadokoro et al. | Sep 2005 | A1 |
20050228255 | Saracen et al. | Oct 2005 | A1 |
20050231138 | Nakanishi et al. | Oct 2005 | A1 |
20050234327 | Saracen et al. | Oct 2005 | A1 |
20050247890 | Norimine et al. | Nov 2005 | A1 |
20050259779 | Abraham-Fuchs et al. | Nov 2005 | A1 |
20060017015 | Sliski et al. | Jan 2006 | A1 |
20060033042 | Groezinger et al. | Feb 2006 | A1 |
20060067468 | Rietzel | Mar 2006 | A1 |
20060126792 | Li | Jun 2006 | A1 |
20060127879 | Fuccione | Jun 2006 | A1 |
20060145088 | Ma | Jul 2006 | A1 |
20060175991 | Fujisawa | Aug 2006 | A1 |
20060192146 | Yanagisawa et al. | Aug 2006 | A1 |
20060204478 | Harats et al. | Sep 2006 | A1 |
20060219948 | Ueno et al. | Oct 2006 | A1 |
20060284562 | Hruby et al. | Dec 2006 | A1 |
20070001128 | Sliski et al. | Jan 2007 | A1 |
20070013273 | Albert et al. | Jan 2007 | A1 |
20070014654 | Haverfield et al. | Jan 2007 | A1 |
20070018120 | Beloussov et al. | Jan 2007 | A1 |
20070023699 | Yamashita et al. | Feb 2007 | A1 |
20070029510 | Hermann et al. | Feb 2007 | A1 |
20070031337 | Schulte | Feb 2007 | A1 |
20070034812 | Ma et al. | Feb 2007 | A1 |
20070051904 | Kaiser et al. | Mar 2007 | A1 |
20070053484 | Chiba et al. | Mar 2007 | A1 |
20070059387 | Stockfleth | Mar 2007 | A1 |
20070075273 | Birgy et al. | Apr 2007 | A1 |
20070083101 | Rietzel | Apr 2007 | A1 |
20070092812 | Caporaso et al. | Apr 2007 | A1 |
20070108922 | Amaldi | May 2007 | A1 |
20070114464 | Birgy et al. | May 2007 | A1 |
20070114471 | Birgy et al. | May 2007 | A1 |
20070114945 | Mattaboni et al. | May 2007 | A1 |
20070145916 | Caporaso et al. | Jun 2007 | A1 |
20070171015 | Antaya | Jul 2007 | A1 |
20070181519 | Khoshnevis | Aug 2007 | A1 |
20070217575 | Kaiser et al. | Sep 2007 | A1 |
20070262269 | Trbojevic | Nov 2007 | A1 |
20070284548 | Kaiser et al. | Dec 2007 | A1 |
20080023644 | Pedroni | Jan 2008 | A1 |
20080029706 | Kaiser et al. | Feb 2008 | A1 |
20080031414 | Coppens | Feb 2008 | A1 |
20080061241 | Rietzel | Mar 2008 | A1 |
20080063147 | Juschka et al. | Mar 2008 | A1 |
20080073591 | Mohr | Mar 2008 | A1 |
20080078942 | Rietzel | Apr 2008 | A1 |
20080093567 | Gall | Apr 2008 | A1 |
20080123816 | Mori et al. | May 2008 | A1 |
20080131419 | Roiz et al. | Jun 2008 | A1 |
20080159478 | Keall et al. | Jul 2008 | A1 |
20080179544 | Kaiser et al. | Jul 2008 | A1 |
20080191142 | Pedroni | Aug 2008 | A1 |
20080191152 | Grozinger et al. | Aug 2008 | A1 |
20080205599 | Hashimoto | Aug 2008 | A1 |
20080218102 | Sliski et al. | Sep 2008 | A1 |
20080219407 | Kaiser et al. | Sep 2008 | A1 |
20080219410 | Gunzert-Marx et al. | Sep 2008 | A1 |
20080219411 | Gunzert-Marx et al. | Sep 2008 | A1 |
20080237494 | Beloussov et al. | Oct 2008 | A1 |
20080237495 | Grozinger et al. | Oct 2008 | A1 |
20080267349 | Rietzel | Oct 2008 | A1 |
20080270517 | Baumann et al. | Oct 2008 | A1 |
20080272284 | Rietzel | Nov 2008 | A1 |
20080290299 | Hansmann et al. | Nov 2008 | A1 |
20080298550 | Otto | Dec 2008 | A1 |
20080301872 | Fahrig et al. | Dec 2008 | A1 |
20080315111 | Sommer | Dec 2008 | A1 |
20090008575 | Okazaki et al. | Jan 2009 | A1 |
20090032742 | Kaiser et al. | Feb 2009 | A1 |
20090050819 | Ma et al. | Feb 2009 | A1 |
20090060130 | Wilkens et al. | Mar 2009 | A1 |
20090065717 | Kaiser et al. | Mar 2009 | A1 |
20090069640 | Rietzel et al. | Mar 2009 | A1 |
20090077209 | Schneider | Mar 2009 | A1 |
20090096179 | Stark et al. | Apr 2009 | A1 |
20090098145 | Mata et al. | Apr 2009 | A1 |
20090101833 | Emhofer et al. | Apr 2009 | A1 |
20090114847 | Grozinger et al. | May 2009 | A1 |
20090140671 | O'Neal, III et al. | Jun 2009 | A1 |
20090140672 | Gall et al. | Jun 2009 | A1 |
20090175414 | Messinger et al. | Jul 2009 | A1 |
20090189095 | Flynn et al. | Jul 2009 | A1 |
20090200483 | Gall et al. | Aug 2009 | A1 |
20090230327 | Rietzel | Sep 2009 | A1 |
20090234237 | Ross et al. | Sep 2009 | A1 |
20090242789 | Tachikawa | Oct 2009 | A1 |
20090261275 | Rietzel | Oct 2009 | A1 |
20090274269 | Foland et al. | Nov 2009 | A1 |
20090296885 | Boeh et al. | Dec 2009 | A1 |
20090309046 | Balakin | Dec 2009 | A1 |
20090309047 | Gunzert-Marx et al. | Dec 2009 | A1 |
20090309520 | Balakin | Dec 2009 | A1 |
20090314960 | Balakin | Dec 2009 | A1 |
20090314961 | Balakin | Dec 2009 | A1 |
20090321656 | Rietzel et al. | Dec 2009 | A1 |
20100006106 | Balakin | Jan 2010 | A1 |
20100006770 | Balakin | Jan 2010 | A1 |
20100008466 | Balakin | Jan 2010 | A1 |
20100014639 | Balakin | Jan 2010 | A1 |
20100014640 | Balakin | Jan 2010 | A1 |
20100020932 | Yi et al. | Jan 2010 | A1 |
20100027745 | Balakin | Feb 2010 | A1 |
20100038552 | Trbojevic | Feb 2010 | A1 |
20100045213 | Sliski et al. | Feb 2010 | A1 |
20100046697 | Balakin | Feb 2010 | A1 |
20100046713 | Nord et al. | Feb 2010 | A1 |
20100060209 | Balakin | Mar 2010 | A1 |
20100090122 | Balakin | Apr 2010 | A1 |
20100091948 | Balakin | Apr 2010 | A1 |
20100126964 | Smith et al. | May 2010 | A1 |
20100127184 | Balakin | May 2010 | A1 |
20100128846 | Balakin | May 2010 | A1 |
20100133444 | Balakin | Jun 2010 | A1 |
20100133446 | Balakin | Jun 2010 | A1 |
20100141183 | Balakin | Jun 2010 | A1 |
20100166150 | Perkins et al. | Jul 2010 | A1 |
20100171045 | Guneysel | Jul 2010 | A1 |
20100171447 | Balakin | Jul 2010 | A1 |
20100176309 | Mackie et al. | Jul 2010 | A1 |
20100207552 | Balakin | Aug 2010 | A1 |
20100230617 | Gall | Sep 2010 | A1 |
20100230620 | Tsoupas et al. | Sep 2010 | A1 |
20100243911 | Fujii et al. | Sep 2010 | A1 |
20100252754 | Brown et al. | Oct 2010 | A1 |
20100264327 | Bonig et al. | Oct 2010 | A1 |
20100266100 | Balakin | Oct 2010 | A1 |
20100288945 | Gnutzmann et al. | Nov 2010 | A1 |
20100296534 | Levecq et al. | Nov 2010 | A1 |
20100301235 | Bert et al. | Dec 2010 | A1 |
20100308235 | Sliski et al. | Dec 2010 | A1 |
20100320404 | Tanke | Dec 2010 | A1 |
20100327187 | Beloussov et al. | Dec 2010 | A1 |
20110006214 | Bonig | Jan 2011 | A1 |
20110009736 | Maltz et al. | Jan 2011 | A1 |
20110011729 | Poehlmann-Martins et al. | Jan 2011 | A1 |
20110027853 | Bert et al. | Feb 2011 | A1 |
20110047469 | Baumann et al. | Feb 2011 | A1 |
20110049396 | Furth et al. | Mar 2011 | A1 |
20110051891 | O'Connor et al. | Mar 2011 | A1 |
20110101236 | Cameron et al. | May 2011 | A1 |
20110118529 | Balakin | May 2011 | A1 |
20110118531 | Balakin | May 2011 | A1 |
20110124976 | Sabczynski et al. | May 2011 | A1 |
20110127443 | Comer et al. | Jun 2011 | A1 |
20110147608 | Balakin | Jun 2011 | A1 |
20110150180 | Balakin | Jun 2011 | A1 |
20110166219 | Stockfleth | Jul 2011 | A1 |
20110180720 | Balakin | Jul 2011 | A1 |
20110180731 | Welsh | Jul 2011 | A1 |
20110182410 | Balakin | Jul 2011 | A1 |
20110186720 | Jongen et al. | Aug 2011 | A1 |
20110196223 | Balakin | Aug 2011 | A1 |
20110200170 | Nord et al. | Aug 2011 | A1 |
20110204262 | Pu et al. | Aug 2011 | A1 |
20110214588 | Grubling et al. | Sep 2011 | A1 |
20110218430 | Balakin | Sep 2011 | A1 |
20110220794 | Censor et al. | Sep 2011 | A1 |
20110220798 | Baurichter et al. | Sep 2011 | A1 |
20110231147 | Takayanagi et al. | Sep 2011 | A1 |
20110233423 | Balakin | Sep 2011 | A1 |
20110238440 | Leuschner | Sep 2011 | A1 |
20110248188 | Brusasco et al. | Oct 2011 | A1 |
20110278477 | Balakin | Nov 2011 | A1 |
20110284757 | Butuceanu et al. | Nov 2011 | A1 |
20110284760 | Balakin | Nov 2011 | A1 |
20110285327 | Begg et al. | Nov 2011 | A1 |
20110297850 | Claereboudt et al. | Dec 2011 | A1 |
20110299657 | Havelange et al. | Dec 2011 | A1 |
20110299919 | Stark et al. | Dec 2011 | A1 |
20110303858 | Bert et al. | Dec 2011 | A1 |
20110306870 | Kuhn | Dec 2011 | A1 |
20110313232 | Balakin | Dec 2011 | A1 |
20120001085 | Fujimoto et al. | Jan 2012 | A1 |
20120043481 | Mansfield et al. | Feb 2012 | A1 |
20120043482 | Prince et al. | Feb 2012 | A1 |
20120056099 | Behrens et al. | Mar 2012 | A1 |
20120056109 | Lomax | Mar 2012 | A1 |
20120069961 | Pomper et al. | Mar 2012 | A1 |
20120077748 | Vidyasagar et al. | Mar 2012 | A1 |
20120099704 | Ruan et al. | Apr 2012 | A1 |
20120112092 | Pomper et al. | May 2012 | A1 |
20120119114 | Brauer | May 2012 | A1 |
20120136194 | Zhang et al. | May 2012 | A1 |
20120143051 | Balakin | Jun 2012 | A1 |
20120205551 | Balakin | Aug 2012 | A1 |
20120207276 | Pomper et al. | Aug 2012 | A1 |
20120209109 | Balakin | Aug 2012 | A1 |
20120223246 | Stephani et al. | Sep 2012 | A1 |
20120224667 | Cheng et al. | Sep 2012 | A1 |
20120242257 | Balakin | Sep 2012 | A1 |
20120248325 | Balakin | Oct 2012 | A1 |
20120256103 | Luzzara | Oct 2012 | A1 |
20120264998 | Fujitaka et al. | Oct 2012 | A1 |
20120267543 | Noda et al. | Oct 2012 | A1 |
20120267544 | Ueda | Oct 2012 | A1 |
20120273665 | Schulte et al. | Nov 2012 | A1 |
20120273666 | Bert et al. | Nov 2012 | A1 |
20120280150 | Jongen | Nov 2012 | A1 |
20120303384 | Stepaniak et al. | Nov 2012 | A1 |
20120305796 | Iseki et al. | Dec 2012 | A1 |
20120313003 | Trbojevic | Dec 2012 | A1 |
20120326722 | Weinberg et al. | Dec 2012 | A1 |
20130001432 | Jongen | Jan 2013 | A1 |
20130043403 | Gordon et al. | Feb 2013 | A1 |
20130053616 | Gall et al. | Feb 2013 | A1 |
20130053617 | Pu et al. | Feb 2013 | A1 |
20130068938 | Heese | Mar 2013 | A1 |
20130072743 | Fieres et al. | Mar 2013 | A1 |
20130072744 | Moskvin et al. | Mar 2013 | A1 |
20130086500 | Kane et al. | Apr 2013 | A1 |
20130090549 | Meltsner et al. | Apr 2013 | A1 |
20130108014 | Tome et al. | May 2013 | A1 |
20130127375 | Sliski et al. | May 2013 | A1 |
20130131424 | Sliski et al. | May 2013 | A1 |
20130131433 | Katscher et al. | May 2013 | A1 |
20130150647 | Chen et al. | Jun 2013 | A1 |
20130163723 | Tacke | Jun 2013 | A1 |
20130187060 | Jongen | Jul 2013 | A1 |
20130208867 | Beckman | Aug 2013 | A1 |
20130209450 | Cohen et al. | Aug 2013 | A1 |
20130211482 | Piipponen | Aug 2013 | A1 |
20130217946 | Balakin | Aug 2013 | A1 |
20130217948 | Mihaylov | Aug 2013 | A1 |
20130217950 | Partanen et al. | Aug 2013 | A1 |
20130218009 | Balakin | Aug 2013 | A1 |
20130221213 | Takayanagi et al. | Aug 2013 | A1 |
20130237425 | Leigh et al. | Sep 2013 | A1 |
20130237822 | Gross et al. | Sep 2013 | A1 |
20130243722 | Basile et al. | Sep 2013 | A1 |
20130245113 | Stockfleth | Sep 2013 | A1 |
20130259335 | Mallya et al. | Oct 2013 | A1 |
20130261430 | Uhlemann | Oct 2013 | A1 |
20130267756 | Totake et al. | Oct 2013 | A1 |
20130277569 | Behrens et al. | Oct 2013 | A1 |
20130299721 | Sasai | Nov 2013 | A1 |
20130303824 | Stephani et al. | Nov 2013 | A1 |
20130324479 | Zhang et al. | Dec 2013 | A1 |
20130345489 | Beloussov et al. | Dec 2013 | A1 |
20140005463 | Jongen | Jan 2014 | A1 |
20140005464 | Bharat et al. | Jan 2014 | A1 |
20140014851 | Asaba | Jan 2014 | A1 |
20140028220 | Bromberg et al. | Jan 2014 | A1 |
20140042934 | Tsutsui | Feb 2014 | A1 |
20140046113 | Fujimoto et al. | Feb 2014 | A1 |
20140061493 | Prieels et al. | Mar 2014 | A1 |
20140066755 | Matteo et al. | Mar 2014 | A1 |
20140077699 | Boswell et al. | Mar 2014 | A1 |
20140091238 | Miyashita et al. | Apr 2014 | A1 |
20140091734 | Gall et al. | Apr 2014 | A1 |
20140094371 | Zwart et al. | Apr 2014 | A1 |
20140094637 | Zwart et al. | Apr 2014 | A1 |
20140094638 | Gall et al. | Apr 2014 | A1 |
20140094639 | Zwart et al. | Apr 2014 | A1 |
20140094640 | Gall et al. | Apr 2014 | A1 |
20140094641 | Gall et al. | Apr 2014 | A1 |
20140094643 | Gall et al. | Apr 2014 | A1 |
20140097920 | Goldie et al. | Apr 2014 | A1 |
20140107390 | Brown et al. | Apr 2014 | A1 |
20140112453 | Prince et al. | Apr 2014 | A1 |
20140113388 | Bitter et al. | Apr 2014 | A1 |
20140121441 | Huber et al. | May 2014 | A1 |
20140128719 | Longfield | May 2014 | A1 |
20140145090 | Jongen | May 2014 | A9 |
20140193058 | Bharat et al. | Jul 2014 | A1 |
20140200448 | Schulte et al. | Jul 2014 | A1 |
20140203186 | Iwamoto et al. | Jul 2014 | A1 |
20140221816 | Franke et al. | Aug 2014 | A1 |
20140239204 | Orton et al. | Aug 2014 | A1 |
20140257011 | Spotts | Sep 2014 | A1 |
20140257099 | Balakin | Sep 2014 | A1 |
20140275699 | Benna et al. | Sep 2014 | A1 |
20140308202 | Matusik et al. | Oct 2014 | A1 |
20140316184 | Fujimoto et al. | Oct 2014 | A1 |
20140330063 | Balakin | Nov 2014 | A1 |
20140332691 | Campbell et al. | Nov 2014 | A1 |
20140336438 | Bharat et al. | Nov 2014 | A1 |
20140350322 | Schulte et al. | Nov 2014 | A1 |
20140369958 | Basile | Dec 2014 | A1 |
20140371076 | Jongen | Dec 2014 | A1 |
20140371511 | Zwart et al. | Dec 2014 | A1 |
20150015167 | Ungaro et al. | Jan 2015 | A1 |
20150030223 | Pearlstein et al. | Jan 2015 | A1 |
20150031933 | Yamamoto et al. | Jan 2015 | A1 |
20150041665 | Hollebeek et al. | Feb 2015 | A1 |
20150076370 | Totake et al. | Mar 2015 | A1 |
20150080633 | Anferov | Mar 2015 | A1 |
20150080634 | Huber et al. | Mar 2015 | A1 |
20150087883 | Boudreau et al. | Mar 2015 | A1 |
20150087885 | Boisseau et al. | Mar 2015 | A1 |
20150087887 | Iwata | Mar 2015 | A1 |
20150087960 | Treffert | Mar 2015 | A1 |
20150090894 | Zwart et al. | Apr 2015 | A1 |
20150099917 | Bula et al. | Apr 2015 | A1 |
20150099918 | Takayanagi et al. | Apr 2015 | A1 |
20150126797 | Aptaker et al. | May 2015 | A1 |
20150146856 | Beckman | May 2015 | A1 |
20150148584 | Gall et al. | May 2015 | A1 |
20150174429 | Zwart et al. | Jun 2015 | A1 |
20150196534 | Vidyasagar et al. | Jul 2015 | A1 |
20150196779 | Tonner | Jul 2015 | A1 |
20150209601 | Benna et al. | Jul 2015 | A1 |
20150217138 | Fujimoto et al. | Aug 2015 | A1 |
20150217140 | Balakin | Aug 2015 | A1 |
20150231411 | O'Neal, III et al. | Aug 2015 | A1 |
20150273239 | Hsu et al. | Oct 2015 | A1 |
20150321025 | Freud et al. | Nov 2015 | A1 |
20150328483 | Odawara et al. | Nov 2015 | A1 |
20150335463 | De Gruytere | Nov 2015 | A1 |
20150335919 | Behar et al. | Nov 2015 | A1 |
20150337393 | Keller et al. | Nov 2015 | A1 |
20150343238 | Balakin | Dec 2015 | A1 |
20150352372 | Takayanagi et al. | Dec 2015 | A1 |
20150352374 | Gattiker et al. | Dec 2015 | A1 |
20150374324 | Nishimura et al. | Dec 2015 | A1 |
20160000387 | Buchsbaum et al. | Jan 2016 | A1 |
20160008631 | Harada et al. | Jan 2016 | A1 |
20160016010 | Schulte et al. | Jan 2016 | A1 |
20160048981 | Pearlstein et al. | Feb 2016 | A1 |
20160059039 | Liu | Mar 2016 | A1 |
20160067316 | Sunavala-Dossabhoy | Mar 2016 | A1 |
20160071623 | Schewiola et al. | Mar 2016 | A1 |
20160074675 | Moskvin et al. | Mar 2016 | A1 |
20160113884 | Lin et al. | Apr 2016 | A1 |
20160136457 | Jung et al. | May 2016 | A1 |
20160144201 | Schulte | May 2016 | A1 |
20160172066 | Claereboudt | Jun 2016 | A1 |
20160172067 | Claereboudt et al. | Jun 2016 | A1 |
20160175052 | Kumar et al. | Jun 2016 | A1 |
20160175617 | Spatola et al. | Jun 2016 | A1 |
20160199667 | Flynn | Jul 2016 | A1 |
20160199670 | Michaud et al. | Jul 2016 | A1 |
20160199671 | Jongen | Jul 2016 | A1 |
20160220846 | Matteo et al. | Aug 2016 | A1 |
20160220847 | Benna et al. | Aug 2016 | A1 |
20160243232 | Pickett | Aug 2016 | A1 |
20160250501 | Balakin | Sep 2016 | A1 |
20160250503 | Balakin et al. | Sep 2016 | A1 |
20160256712 | Vahala et al. | Sep 2016 | A1 |
20160263404 | Mougenot | Sep 2016 | A1 |
20160270203 | Ungaro et al. | Sep 2016 | A1 |
20160271424 | Lee et al. | Sep 2016 | A1 |
20160287899 | Park et al. | Oct 2016 | A1 |
20160296766 | El Fakhri et al. | Oct 2016 | A1 |
20160303399 | Balakin | Oct 2016 | A1 |
20160331999 | Hartman et al. | Nov 2016 | A1 |
20170128746 | Zwart | May 2017 | A1 |
20170157422 | Zwart et al. | Jun 2017 | A1 |
20170157424 | Zwart et al. | Jun 2017 | A1 |
20170157425 | Zwart et al. | Jun 2017 | A1 |
20170182338 | Zwart et al. | Jun 2017 | A1 |
Number | Date | Country |
---|---|---|
2629333 | May 2007 | CA |
1377521 | Oct 2002 | CN |
1537657 | Oct 2004 | CN |
1816243 | Aug 2006 | CN |
101061759 | Oct 2007 | CN |
101145409 | Mar 2008 | CN |
101361156 | Feb 2009 | CN |
101932361 | Dec 2010 | CN |
101933405 | Dec 2010 | CN |
101933406 | Dec 2010 | CN |
102905761 | Jan 2013 | CN |
2753397 | Jun 1978 | DE |
3148100 | Jun 1983 | DE |
3530446 | Mar 1986 | DE |
3711245 | Oct 1988 | DE |
4101094 | May 1992 | DE |
4411171 | Oct 1995 | DE |
19907098 | Aug 2000 | DE |
102011089235 | Aug 2012 | DE |
0194728 | Sep 1986 | EP |
0208163 | Jan 1987 | EP |
0221987 | May 1987 | EP |
0222786 | May 1987 | EP |
0277521 | Aug 1988 | EP |
0306966 | Mar 1989 | EP |
0388123 | Sep 1990 | EP |
0465597 | Jan 1992 | EP |
0499253 | Aug 1992 | EP |
0751532 | Jan 1997 | EP |
0776595 | Jun 1997 | EP |
0864337 | Sep 1998 | EP |
0911064 | Apr 1999 | EP |
1069809 | Jan 2001 | EP |
1153398 | Nov 2001 | EP |
1294445 | Mar 2003 | EP |
1348465 | Oct 2003 | EP |
1358908 | Nov 2003 | EP |
1371390 | Dec 2003 | EP |
1402923 | Mar 2004 | EP |
1430932 | Jun 2004 | EP |
1454653 | Sep 2004 | EP |
1454654 | Sep 2004 | EP |
1454655 | Sep 2004 | EP |
1454656 | Sep 2004 | EP |
1454657 | Sep 2004 | EP |
1477206 | Nov 2004 | EP |
1605742 | Dec 2005 | EP |
1738798 | Jan 2007 | EP |
1826778 | Aug 2007 | EP |
1949404 | Jul 2008 | EP |
2114529 | Nov 2009 | EP |
2183753 | May 2010 | EP |
2227295 | Sep 2010 | EP |
2232961 | Sep 2010 | EP |
2232962 | Sep 2010 | EP |
2363170 | Sep 2011 | EP |
2363171 | Sep 2011 | EP |
2394498 | Dec 2011 | EP |
2514482 | Oct 2012 | EP |
2524718 | Nov 2012 | EP |
3035776 | Jun 2016 | EP |
3088048 | Nov 2016 | EP |
2560421 | Aug 1985 | FR |
2911843 | Aug 2008 | FR |
0957342 | May 1964 | GB |
2015821 | Sep 1979 | GB |
2361523 | Oct 2001 | GB |
S47-028762 | Dec 1972 | JP |
S48-108098 | Dec 1973 | JP |
S57-162527 | Oct 1982 | JP |
58-141000 | Aug 1983 | JP |
S61-80800 | Apr 1986 | JP |
61-225798 | Oct 1986 | JP |
62-150804 | Jul 1987 | JP |
62-186500 | Aug 1987 | JP |
63-149344 | Jun 1988 | JP |
63-218200 | Sep 1988 | JP |
63-226899 | Sep 1988 | JP |
64-89621 | Apr 1989 | JP |
01-276797 | Nov 1989 | JP |
01-302700 | Dec 1989 | JP |
4-94198 | Mar 1992 | JP |
H06-036893 | Feb 1994 | JP |
H06-233831 | Aug 1994 | JP |
07-260939 | Oct 1995 | JP |
07-263196 | Oct 1995 | JP |
08-173890 | Jul 1996 | JP |
08-264298 | Oct 1996 | JP |
09-162585 | Jun 1997 | JP |
10-071213 | Mar 1998 | JP |
11-47287 | Feb 1999 | JP |
H1128252 | Feb 1999 | JP |
11-102800 | Apr 1999 | JP |
11-243295 | Sep 1999 | JP |
2000-243309 | Sep 2000 | JP |
2000-294399 | Oct 2000 | JP |
2001-6900 | Jan 2001 | JP |
2001-009050 | Jan 2001 | JP |
2001-129103 | May 2001 | JP |
2001-276238 | Oct 2001 | JP |
2001-346893 | Dec 2001 | JP |
2002-164686 | Jun 2002 | JP |
2003-504628 | Feb 2003 | JP |
2003-517755 | May 2003 | JP |
2004-031115 | Jan 2004 | JP |
2005-526578 | Sep 2005 | JP |
2006-032282 | Feb 2006 | JP |
2006341010 | Dec 2006 | JP |
2007-307223 | Nov 2007 | JP |
2008-068092 | Mar 2008 | JP |
2008-507826 | Mar 2008 | JP |
04-128717 | Jul 2008 | JP |
04-129768 | Aug 2008 | JP |
2009-515671 | Apr 2009 | JP |
2009-516905 | Apr 2009 | JP |
04-273409 | Jun 2009 | JP |
04-337300 | Sep 2009 | JP |
43-23267 | Sep 2009 | JP |
2010-536130 | Nov 2010 | JP |
2011-505191 | Feb 2011 | JP |
2011-505670 | Feb 2011 | JP |
2011-507151 | Mar 2011 | JP |
05-046928 | Oct 2012 | JP |
2012-223259 | Nov 2012 | JP |
2013-106981 | Jun 2013 | JP |
05-341352 | Nov 2013 | JP |
300137 | Jun 1969 | SU |
569635 | Aug 1977 | SU |
200930160 | Jul 2009 | TW |
200934682 | Aug 2009 | TW |
200939908 | Sep 2009 | TW |
200940120 | Oct 2009 | TW |
WO-8607229 | Dec 1986 | WO |
WO-9012413 | Oct 1990 | WO |
WO-9203028 | Feb 1992 | WO |
WO-9302536 | Feb 1993 | WO |
WO-9817342 | Apr 1998 | WO |
WO-199939385 | Aug 1999 | WO |
WO-200040064 | Jul 2000 | WO |
WO-200049624 | Aug 2000 | WO |
WO-01126569 | Apr 2001 | WO |
WO-2001026230 | Apr 2001 | WO |
WO-0207817 | Jan 2002 | WO |
WO-2003039212 | May 2003 | WO |
WO-2003092812 | Nov 2003 | WO |
WO-2004026401 | Apr 2004 | WO |
WO-2004101070 | Nov 2004 | WO |
WO-2006-012467 | Feb 2006 | WO |
WO-2007061937 | May 2007 | WO |
WO-2007084701 | Jul 2007 | WO |
WO-2007130164 | Nov 2007 | WO |
WO-2007145906 | Dec 2007 | WO |
WO-2008030911 | Mar 2008 | WO |
WO-2008081480 | Jul 2008 | WO |
WO-2009048745 | Apr 2009 | WO |
WO-2009070173 | Jun 2009 | WO |
WO-2009070588 | Jun 2009 | WO |
WO-2009073480 | Jun 2009 | WO |
WO-2014018706 | Jan 2014 | WO |
WO-2014018876 | Jan 2014 | WO |
WO-2015003111 | Jan 2015 | WO |
WO-2015095678 | Jun 2015 | WO |
WO-2015107660 | Jul 2015 | WO |
WO-2016201348 | Dec 2016 | WO |
WO-2017082984 | May 2017 | WO |
WO-2018128822 | Jul 2018 | WO |
WO-2019006253 | Jan 2019 | WO |
Entry |
---|
18th Japan Conference on Radiation and Radioisotopes [Japanese], Nov. 25-27, 1987, 9 pages. |
510(k) Summary: Ion Beam Applications S.A., FDA, Jul. 12, 2001, 5 pages. |
510(k) Summary: Optivus Proton Beam Therapy System, Jul. 21, 2000, 5 pages. |
Abrosimov et al., 1000MeV Proton Beam Therapy facility at Petersburg Nuclear Physics Institute Synchrocyclotron, Medical Radiology (Moscow) 32, 10 (1987) revised in Journal of Physics, Conference Series 41, 2006, pp. 424-432, Institute of Physics Publishing Limited. |
Abrosimov et al., Neutron Time-of-flight Spectrometer Gneis at the Gatchina 1 GeV Protron Syncrhocyclotron, Mar. 9, 1985 and revised form Jul. 31, 1985, Lemingrad Nuclear Physics Institute, Gatchina, 188350, USSR (15 pages). |
Adachi et al., A 150MeV FFAG Synchrotron with Return-Yoke Free Magent, Proceedings of the 2001 Particle Accelerator Conference, Chicago, 2001, 3 pages. |
Ageyev et al., The IHEP Accelerating and Storage Complex (UNK) Status Report, 11th International Conference on High-Energy Accelerators, 1980, pp. 60-70. |
Agosteo et al., Maze Design of a gantry room for proton therapy, Nuclear Instruments & Methods in Physics Research, 1996, Section A, 382, pp. 573-582. |
Alexeev et al., R4 Design of Superconducting Magents for Proton Synchrotrons, Proceedings of the Fifth International Cryogenic Engineering Conference, 197 4, pp. 531-533. |
Allardyce et al., Performance and Prospects of the Reconstructed CERN 600 MeV Synchrocyclotron, IEEE Transactions on Nuclear Science USA, Jun. 1977, ns-24:(3) 1631-1633. |
Alonso, Magnetically Scanned Ion Beams for Radiation Therapy, Accelerator & Fusion Research Division, Lawrence Berkeley Laboratory, Berkeley, CA, Oct. 1988, 13 pages. |
Amaldi et al., The Italian project for a hadrontherapy centre Nuclear Instruments and Methods in Physics Research A, 1995, 360, pp. 297-301. |
Amaldi, Overview of the world landscape of Hadrontherapy and the projects of the TERA foundation, Physica Medica, An International journal Devoted to the Applications of Physics to Medicine and Biology, Jul. 1998, vol. XIV, Supplement 1, 6th Workshop on Heavy Charged Particles in Biology and Medicine, Instituto Scientific Europeo (ISE), Sep. 29-Oct. 1, 1977, Baveno, pp. 76-85. |
An Accelerated Collaboration Meets with Beaming Success, Lawrence Livermore National Laboratory, Apr. 12, 2006, S&TR, Livermore, California, pp. 1-3, http://www.llnl.gov/str/April06/Caporaso.html. |
Anferov et al., Status of the Midwest Proton Radiotherapy Institute, Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 699-701. |
Anferov et al., The Indiana University Midwest Proton Radiation Institute, Proceedings of the 2001 Particle Accelerator Conference, 2001, Chicago, pp. 645-647. |
Appun, Various problems of magnet fabrication for high-energy accelerators, Journal for All Engineers Interested in the Nuclear Field, 1967, 11 pages 10-16 (1967) [Lang.: German], English bibliographic information (httn://www.osti.1mv/enernvcitations/nroduct.biblio.isn?ostiid=4442292). |
Arduini et al. Physical specifications of clinical proton beams from a synchrotron, Med. Phys, Jun. 1996, 23 ( 6): 939-951. |
Badano et al., Proton-Ion Medical Machine Study (PIMMS) Part I, PIMMS, Jan. 1999, 238 pages. |
Beam Delivery and Properties, Journal of the ICRU, 2007, 7(2):20 pages. |
Beeckman et al., Preliminary design of a reduced cost proton therapy facility using a compact, high field isochronous cyclotron, Nuclear Instruments and Methods in Physics Research B56/57, 1991, pp. 1201-1204. |
Bellomo et al., The Superconducting Cyclotron Program at Michigan State University, Bulletin of the American Physical Society, Sep. 1980, 25(7):767. |
Benedikt and Carli, Matching to Gantries for Medical Synchrotrons IEEE Proceedings of the 1997 Particle Accelerator Conference, 1997, pp. 13 79-13 81. |
Bieth et al., A Very Compact Protontherapy Facility Based on an Extensive Use of High Temperature Superconductors (HTS) Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Jun. 14-19, 1998, pp. 669-672. |
Bigham, Magnetic Trim Rods for Superconducting Cyclotrons, Nuclear Instruments and Methods (North-Holland Publishing Co.), 1975, 141:223-228. |
Bimbot, First Studies of the External Beam from the Orsay S.C. 200 MeV, Institut de Physique Nucleaire, BP 1, Orsay, France, IEEE, 1979, pp. 1923-1926. |
Blackmore et al., Operation of the Triumf Proton Therapy Facility, IEEE Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, 3:3831-3833. |
Bloch, The Midwest Proton Therapy Center, Application of Accelerators in Research and Industry, Proceedings of the Fourteenth Int'l. Conf, Part Two, Nov. 1996, pp. 1253-1255. |
Blosser et al., A Compact Superconducting Cyclotron for the Production of High Intensity Protons, Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, 1:1054-1056. |
Blosser et al., Advances in Superconducting Cyclotrons at Michigan State University, Proceedings of the 11th International Conference on Cyclotrons and their Applications, Oct. 1986, pp. 157-167, Tokyo. |
Blosser et al., Characteristics of a 400 (Q2/A) MeV Super-Conducting Heavy-Ion Cyclotron, Bulletin of the American Physical Society, Oct. 1974, p. 1026. |
Blosser et al., Medical Accelerator Projects at Michigan State Univ. IEEE Proceedings of the 1989 Particle Accelerator Conference, Mar. 20-23, 1989, 2:742-746. |
Blosser et al., Problems and Accomplishments of Superconducting Cyclotrons, Proceedings of the 14th International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 674-684. |
Blosser et al., Superconducting Cyclotron for Medical Application, IEEE Transactions on Magnetics, Mar. 1989, 25(2): 1746-1754. |
Blosser et al., Superconducting Cyclotrons, Seventh International Conference on Cyclotrons and their Applications, Aug. 19-22, 1975, pp. 584-594. |
Blosser, Application of Superconductivity in Cyclotron Construction, Ninth International Conference on Cyclotrons and their Applications, Sep. 1981, pp. 147-157. |
Blosser, Applications of Superconducting Cyclotrons, Twelfth International Conference on Cyclotrons and Their Applications, May 8-12, 1989, pp. 137-144. |
Blosser, Future Cyclotrons, AIP, The Sixth International Cyclotron Conference, 1972, pp. 16-32. |
Blosser, H., Present and Future Superconducting Cyclotrons, Bulletin of the American Physical Society, Feb. 1987, 32(2):171 Particle Accelerator Conference, Washington, D.C. |
Blosser, H.G., Superconducting Cyclotrons at Michigan State University, Nuclear Instruments & Methods in Physics Research, 1987,vol. B 24/25, part II, pp. 752-756. |
Blosser, Medical Cyclotrons, Physics Today, Special Issue Physical Review Centenary, Oct. 1993, pp. 70-73. |
Blosser, Preliminary Design Study Exploring Building Features Required for a Proton Therapy Facility for the Ontario Cancer Institute, Mar. 1991, MSUCL-760a, 53 pages. |
Blosser, Progress on the Coupled Superconducting Cyclotron Project, Bulletin of the American Physical Society, 1993 (p. 3). |
Blosser, Synchrocyclotron Improvement Programs, IEEE Transactions on Nuclear Science USA, Jun. 1969, 16(3):Part I, pp. 405-414. |
Blosser, The Michigan State University Superconducting Cyclotron Program, Nuclear Science, Apr. 1979, NS-26(2):2040-2047. |
Botha et al., A New Multidisciplinary Separated-Sector Cyclotron Facility, IEEE Transactions on Nuclear Science, 1977, NS-24(3): 1118-1120. |
Boyer, A. et al., Basic Applications of Multi-leaf Collimators: Report of Task Group No. 50-Radiation Therapy Committee, AAPM Report No. 72, American Association of Physicists in Medicine by Medical Physics Publishing, 62 pages (2001). |
Bues, M. et al., Therapeutic Step and Shoot Proton Beam Spot-Scanning With a Multi-Leaf Collimator: A Monte Carlo Study, Radiation Protection Dosimetry, 115(1-4):164-169 (2005). |
Chichili et al., Fabrication ofNb3Sn Shell-Type Coils with Pre-Preg Ceramic Insulation, American Institute of Physics Conference Proceedings, AIP USA, No. 711, (XP-002436709, ISSN: 0094-243X), 2004, pp. 450-457. |
Chong et al., Radiology Clinic North American 7, 3319, 1969, 27 pages. |
Chu et al., Instrumentation for Treatment of Cancer Using Proton and Light-ion Beams, Review of Scientific Instruments, Aug. 1993, 64 (8):2055-2122. |
Chu et al., Performance Specifications for Proton Medical Facility, Lawrence Berkeley Laboratory, University of California, Mar. 1993, 128 pages. |
Chu, Instrumentation in Medical Systems, Accelerator and Fusion Research Division, Lawrence Berkeley Laboratory, University of California, Berkeley, CA, May 1995, 9 pages. |
Cole et al., Design and Application of a Proton Therapy Accelerator, Fermi National Accelerator Laboratory, IEEE, 1985, 5 pages. |
Collins, et al., The Indiana University Proton Therapy System, Proceedings of EPAC 2006, Edinburgh, Scotland, 2006, 3 pages. |
Communication pursuant to Article 94(3) EPC for EP14830919.8, 6 pages (May 12, 2017). |
Communication pursuant to Rules 161(1) and 162 EPC in EP14830919.8, 2 pages (Sep. 2, 2016). |
Communication under Rule 71(3) EPC for EP14830919.8, 113 pages (May 2, 2018). |
Conradi et al., Proposed New Facilities for Proton Therapy at iThemba Labs, Proceedings of EPAC, 2002, pp. 560-562. |
C/E Source of Ions for Use in Sychro-Cyclotrons Search, Jan. 31, 2005, 9 pages. |
Cosgrove et al., Microdosimetric Studies on the Orsay Proton Synchrocyclotron at 73 and 200 MeV, Radiation Protection Dosimetry, 1997, 70(1-4):493-496. |
Coupland, High-field (5 T) pulsed superconducting dipole magnet, Proceedings of the Institution of Electrical EnRineers, Jul. 1974, 121(7):771-778. |
Coutrakon et al. Proton Synchrotrons for Cancer Therapy, Application of Accelerators in Research and Industry—Sixteenth International Conf., American Institute of Physics, Nov. 1-5, 2000, vol. 576, pp. 861-864. |
Coutrakon et al., A prototype beam delivery system for the proton medical accelerator at Loma Linda, Medical Physics, Nov./Dec. 1991, 18(6):1093-1099. |
CPAC Highlights Its Proton Therapy Program at ESTRO Annual Meeting, TomoTherapy Incorporated, Sep. 18, 2008, Madison, Wisconsin, pp. 1-2. |
Cuttone, Applications of a Particle Accelerators in Medical Physics, Istituto Nazionale di Fisica Nucleare-Laboratori Nazionali del Sud, V.S. Sofia, 44 Cantania, Italy, Jan. 2010, 17 pages. |
Daartz, J. et al., Characterization of a mini-multileaf collimator in a proton beamline, Med. Phys., 36(5):9 pages (2009). |
Dahl P, Superconducting Magnet System, American Institute of Physics, AIP Conference Proceedings, 1987-1988, 2: 1329-1376. |
Dialog Search, Jan. 31, 2005, 17 pages. |
Dugan et al., Tevatron Status IEEE, Particle Accelerator Conference, Accelerator Science & Technology, 1989, pp. 426-430. |
Eickhoff et al., The Proposed Accelerator Facility for Light Ion Cancer Therapy in Heidelberg, Proceedings of the 1999 Particle Accelerator Conference, New York, 1999, pp. 2513-2515. |
Enchevich et al., Minimizing Phase Losses in the 680 MeV Synchrocyclotron by Correcting the Accelerating Voltage Amplitude, Atomnaya Energiya, 1969, 26:(3):315-316. |
Endo et al., Compact Proton and Carbon Ion Synchrotrons for Radiation Therapy, Proceedings of EPAC 2002, Paris France, 2002, pp. 2733-2735. |
File History of U.S. Appl. No. 13/303,110. |
File History of U.S. Appl. No. 61/843,092, 84 pages (downloaded Oct. 14, 2016). |
File History of U.S. Appl. No. 61/900,455, 43 pages (downloaded Oct. 14, 2016). |
File History of U.S. Appl. No. 61/946,074, 137 pages (downloaded Oct. 14, 2016). |
Final Office Action for U.S. Appl. No. 14/937,048, 52 pages (dated Mar. 1, 2018). |
Final Office Action for U.S. Appl. No. 15/438,544, 31 pages (dated Mar. 1, 2018). |
Final Office Action for U.S. Appl. No. 14/137,854, 29 pages (dated Sep. 19, 2016). |
First Office Action (English translation) for JP2016-541203, 10 pages (dated Jul. 31, 2017). |
First Office Action (Japanese translation) for JP2016-541203, 7 pages (dated Jul. 31, 2017). |
First Office Action for CN201480070002.6 (Chinese translation), 9 pages (dated Apr. 11, 2018). |
First Office Action for CN201480070002.6 (English translation), 12 pages (dated Apr. 11, 2018). |
Flanz et al., Large Medical Gantries, Particle Accelerator Conference, Massachusetts General Hospital, 1995, pp. 1-5. |
Flanz et al., Operation of a Cyclotron Based Proton Therapy Facility, Massachusetts General Hospital, Boston, MA 02114, pp. 1-4, retrieved from Internet in 2009. |
Flanz et al., The Northeast Proton Therapy Center at Massachusetts General Hospital, Fifth Workshop on Heavy Charge Particles in Biology and Medicine, GSI, Darmstadt, Aug. 1995, 11 pages. |
Flanz et al., Treating Patients with the NPTC Accelerator Based Proton Treatment Facility, Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 690-693. |
Flood and Frazier, The Wide-Band Driven RF System for the Berkeley 88-Inch Cyclotron, American Institute of Physics, Conference Proceedings., No. 9, 1972, 459-466. |
Foster and Kashikhin, Superconducting Superferric Dipole Magent with Cold Iron Core for the VLHC, IEEE Transactions on Applied Superconductivity, Mar. 2002, 12(1):111-115. |
Fredriksson, Albin, Robust optimization of radiation therapy accounting for geometric uncertainty, Doctoral Thesis, 57 pages (2013). |
Friesel et al., Design and Construction Progress on the IUCF Midwest Proton Radiation Institute, Proceedings of EPAC 2002, 2002, pp. 2736-2738. |
Fukumoto et al., A Proton Therapy Facility Plan Cyclotrons and their Applications, Proceedings of the 13th International Conference, Vancouver, Canada, Jul. 6-10, 1992, pp. 258-261. |
Fukumoto, Cyclotron Versus Synchrotron for Proton Beam Therapy, KEK Prepr., No. 95-122, Oct. 1995, pp. 533-536. |
Gelover, E. et al., A method for modeling laterally asymmetric proton beamlets resulting from collimation, Medical Physics, 42:1321-1334 (2015). |
Goto et al., Progress on the Sector Magnets for the Riken SRC, American Institute of Physics, 714 CP600, Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 319-323. |
Graffman et al., Design Studies for a 200 MeV Proton Clinic for Radiotherapy, AIP Conference Proceedings: Cyclotrons—1972, 1972, No. 9, pp. 603-615. |
Graffman, et. al. Proton radiotherapy with the Uppsala cyclotron. Experience and plans Strahlentherapie, 1985, 161(12):764-770. |
Graffman, S., et al., Clinical Trials in Radiotherapy and the Merits of High Energy Protons, Acta Radiol. Therapy Phys. Biol. 9:1-23 (1970). |
Hede, Research Groups Promoting Proton Therapy Lite, Journal of the National Cancer Institute, Dec. 6, 2006, 98(23):1682-1684. |
Heinz, Superconducting Pulsed Magnetic Systems for High-Energy Synchrotrons, Proceedings of the Fourth International Cryogenic Engineering Conference, May 24-26, 1972, pp. 55-63. |
Hentschel et al., Plans for the German National Neutron Therapy Centre with a Hospital-Based 70 MeV Proton Cyclotron at University Hospital Essen/Germany, Cyclotrons and their Applications, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Franco, Jun. 14-19, 1998, pp. 21-23. |
Hepburn et al., Superconducting Cyclotron Neutron Source for Therapy, International Journal of Radiation Oncology Biology Physics, vol. 3 complete, 1977, pp. 387-391. |
Hirabayashi, Development of Superconducting Magnets for Beam Lines and Accelerator at KEK, IEEE Transaction on Magnetics, Jan. 1981, Mag-17(1 ):728-731. |
Hyer, D. et al., A dynamic collimation system for penumbra reduction in spot-scanning proton therapy: Proof of concept; Medical Physics, 41(9):091701-1-091701-9 (2014). |
Indiana's mega-million proton therapy cancer center welcomes its first patients [online] Press release, Health & Medicine Week, 2004, retrieved from NewsRx.com, Mar. 1, 2004, pp. 119-120. |
International Preliminary Report on Patentability for PCT/US2014/071448, 14 pages (dated Jun. 30, 2016). |
International Search Report and Written Opinion issued in corresponding PCT application No. PCT/US2014/071448 dated Jul. 24, 2015 (18 pages). |
International Search Report for PCT/US2016/048037, 11 pages (dated Feb. 6, 2017). |
International Search Report for PCT/US2017/067677 (High-Speed Energy Switching, filed Dec. 20, 2017), issued by ISA/US, 4 pages (dated Apr. 30, 2018). |
Invitation to Pay Additional Fees and, where applicable, protest fee issued in PCT application PCT/US2014/071448 dated Apr. 13, 2015 (11 pages). |
Invitation to Pay Additional Fees and, where applicable, protest fee issued in PCT application PCT/US2016/048037 dated Oct. 20, 2016 (8 pages). |
Ishibashi and Mcinturff, Stress Analysis of Superconducting 1 OT Magnets for Synchrotron, Proceedings of the Ninth International Cryogenic Engineering Conference, May 11-14, 1982, pp. 513-516. |
Ishibashi and Mcinturff, Winding Design Study of Superconducting 10 T Dipoles for a Synchrotron, IEEE Transactions on Magentics, May 1983, MAG-19(3):1364-1367. |
Jahnke et al., First Superconducting Prototype Magnets for a Compact Synchrotron Radiation Source in Operation, IEEE Transactions on Magnetics, Mar. 1988, 24(2):1230-1232. |
Jones and Dershem, Synchrotron Radiation from Proton in a 20 TEV, 10 TESLA Superconducting Super Collider Proceedings of the 12th International Conference on High-Energy Accelerator, Aug. 11-16, 1983, pp. 138-140. |
Jones and Mills, The South African National Accelerator Centre: Particle Therapy and Isotope Production Programmes, Radiation Physics and Chemistry, Apr.-Jun. 1998, 51 ( 4-6):571-578. |
Jones et al., Status Report of the NAC Particle Therapy Programme, Stralentherapie und Onkologie, vol. 175, Suppl. II, Jun. 1999, pp. 30-32. |
Jones, Present Status and Future Trends of Heavy Particle Radiotherapy, Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 14-19, 1998, pp. 13-20. |
Jones, Progress with the 200 MeV Cyclotron Facility at the National Accelerator Centre, Commission of the European Communities Radiation Protection Proceedings, Fifth Symposium on Neutron Dosimetry, Sep. 17-21, 1984, vol. II, pp. 989-998. |
Jongen et al., Development of a Low-cost Compact Cyclotron System for Proton Therapy, National Institute of Radiol. Sci,1991, No. 81, DD. 189-200. |
Jongen et al., Progress report on the IBA-SHI small cyclotron for cancer therapy Nuclear Instruments and Methods in Physics Research, Section B, vol. 79, issue 1-4, 1993, pp. 885-889. |
Jongen et al., The proton therapy system for MGH's NPTC: equipment description and progress report, Bulletin du Cancer/Radiotherapie, Proceedings of the meeting of the European Heavy Particle Therapy Group, 1996, 83(Suppl. 1):219-222. |
Jongen et al., The proton therapy system for the NPTC: Equipment Description and progress report, Nuclear Instruments and methods in physics research, 1996, Section B, 113(1 ): 522-525. |
Kanai et al., Three-dimensional Beam Scanning for Proton Therapy, Nuclear Instruments and Methods in Physic Research, Sep. 1, 1983, The Netherlands, 214(23):491-496. |
Karlin et al., Medical Radiology (Moscow), 1983, 28, 13. |
Karlin et al., The State and Prospects in the Development of the Medical Proton Tract on the Synchrocyclotron in Gatchina, Med. Radial., Moscow, 28(3):28-32 (Mar. 1983)(German with English Abstract on end of p. 32). |
Kats and Druzhinin, Comparison of Methods for Irradiation Prone Patients, Atomic Energy, Feb. 2003, 94(2): 120-123. |
Kats and Onosovskii, A Planar Magnetooptical System for the Irradiation of a Lying Patient with a Proton Beam from Various Directions, Instruments and Experimental Techniques, 1996, 39(1):127-131. |
Kats and Onosovskii, A Simple, Compact, Flat System for the Irradiation of a Lying Patient with a Proton Beam from Different Directions, Instruments and Experimental Techniques, 1996, 39(1):132-134. |
Khoroshkov et al., Moscow Hospital-Based Proton Therapy Facility Design, Am. Journal Clinical Oncology: CCT, Apr. 1994, 17(2):109-114. |
Kim and Blosser, Optimized Magnet for a 250 MeV Proton Radiotherapy Cyclotron, Cyclotrons and Their Applications 2001, May 2001, Sixteenth International Conference, pp. 345-347. |
Kim and Yun, A Light-Ion Superconducting Cyclotron System for Multi-Disciplinary Users, Journal of the Korean Physical Society, Sep. 2003, 43(3):325-331. |
Kim et al., Construction of 8T Magnet Test Stand for Cyclotron Studies, IEEE Transactions on Applied Superconductivity, Mar. 1993, 3(1):266-268. |
Kim et al., Design Study of a Superconducting Cyclotron for Heavy Ion Therapy, Cyclotrons and Their Applications 2001, Sixteenth International Conference, May 13-17, 2001, pp. 324-326. |
Kim et al., Trim Coil System for the Riken Cyclotron Ring Cyclotron, Proceedings of the 1997 Particle Accelerator Conference, IEEE, Dec. 1981, vol. 3, pp. 214-235 or 3422-3424, 1998. |
Kim, An Eight Tesla Superconducting Magnet for Cyclotron Studies, Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1994, 13 8 pages. |
Kimstrand, Beam Modelling for Treatment Planning of Scanned Proton Beams, Digital Comprehensive Summaries of Uppsala dissertations from the Faculty of Medicine 330, Uppsala Universitet, 2008, 58 pages. |
Kishida and Yano, Beam Transport System for the RIKEN SSC (II), Scientific Papers of the Institute of Physical and Chemical Research, Dec. 1981, 75(4):214-235. |
Koehler et al., Range Modulators for Protons and Heavy Ions, Nuclear Instruments and Methods, 1975, vol. 131, pp. 437-440. |
Koto and Tsujii, Future of Particle Therapy, Japanese Journal of Cancer Clinics, 2001, 47(1):95-98 [Lang.: Japanese], English abstract (http://sciencelinks.j12/jeast/article/200206/000020020601A05 I I 453 .nhn). |
Kraft et al., Hadrontherapy in Oncology, U. Amaldi and Larrsson, editors Elsevier Science, 1994, 161 pages. |
Krevet et al., Design of a Strongly Curved Superconducting Bending Magnet for a Compact Synchrotron Light Source, Advances in Cryogenic Engineering, 1988, vol. 33, pp. 25-32. |
Laisne et al., The Orsay 200 MeV Synchrocyclotron, IEEE Transactions on Nuclear Science, Apr. 1979, NS-26(2):1919-1922. |
Larsson, B., et al., “The High-Energy Proton Beam as a Neurosurgical Tool,” Nature vol. 182, pp. 1222-1223 (1958). |
Larsson, Biomedical Program for the Converted 200-MeV Synchrocyclotron at the Gustaf Werner Institute, Radiation Research, 1985, 104:S310-S318. |
Lawrence et al., Heavy particles in acromegaly and Cushing's Disease, in Endocrine and Norendocrine Hormone Producing Tumors (Year Book Medical Chicago, 1973, pp. 29-61. |
Lawrence et al., Successful Treatment of Acromegaly: Metabolic and Clinical Studies in 145 Patients, The Journal of Clinical Endrocrinology and Metabolism, Aug. 1970, 31(2), 21 pages. |
Lawrence et al., Treatment of Pituitary Tumors, (Excerpta medica, Amsterdam/American Elsevier, New York, 1973, pp. 253-262. |
Lawrence, J.H., Proton Irradiation of the Pituitary Cancer, vol. 10, pp. 795-798 (1957). |
Lecroy et al., Viewing Probe for High Voltage Pulses, Review of Scientific Instruments USA, Dec. 1960, 31(12):1354. |
Lin et al., Principles and 10 Year Experience of the Beam Monitor System at the PSI Scanned Proton Therapy Facility, Center for Proton Radiation Therapy, Paul Scherrer Institute, CH-5232, Villigen PSI, Switzerland, 2007, 21 pages. |
Linfoot et al., Acromegaly, in Hormonal Proteins and Peptides, edited by C.H. Li, 1975, pp. 191-246. |
Literature Author and Keyword Search, Feb. 14, 2005, 44 pages. |
Literature Keyword Search, Jan. 24, 2005, 98 pages. |
Literature Search and Keyword Search for Synchrocyclotron, Jan. 25, 2005, 68 pages. |
Literature Search by Company Name/Component Source, Jan. 24, 2005, 111 pages. |
Literature Search, Jan. 26, 2005, 37 pages. |
Livingston, M.S., et al. A Capillary Ion Source for the Cyclotron, Review Science Instruments, vol. 10, p. 9. 63-67, (1939). |
LLNL, UC Davis Team Up to Fight Cancer, Lawrence Livermore National Laboratory, Apr. 28, 2006, SF-06-04-02, Livermore, California, pp. 1-4. |
Machine translation of JP11-028252A from jpo website Jul. 17, 2015. |
Mandrillon, High Energy Medical Accelerators, EPAC 90, 2nd European Particle Accelerator Conference, Jun. 12-16, 1990, 2:54-58. |
Marchand et al., IBA Proton Pencil Beam Scanning: an Innovative Solution for Cancer Treatment, Proceedings of EP AC 2000, Vienna, Austria, 3 pages. |
Marti et al., High Intensity Operation of a Superconducting Cyclotron, Proceedings of the I 4the International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 45-48 (Oct. 1995). |
Martin, Operational Experience with Superconducting Synchrotron Magnets Proceedings of the 1987 IEEE Particle Accelerator Conference, Mar. 16-19, 1987, vol. 3 of 3: 1379-1382. |
Meote et al., ETOILE Hadrontherapy Project, Review of Design Studies Proceedings of EPAC 2002, 2002, pp. 2745-2747. |
Miyamoto et al., Development of the Proton Therapy System, The Hitachi Hyoron, 79(10):775-775 779 (1997) [Lang: Japanese]. |
Moignier, A. et al., Toward improved target conformity for two spot scanning proton therapy delivery systems using dynamic collimation, Medical Physics, 43:1421-1427 (2014). |
Montelius et al., The Narrow Proton Beam Therapy Unit at the Svedberg Laboratory in Uppsala, ACTA Oncologica, 1991, 30:739-745. |
Moser et al., Nonlinear Beam Optics with Real Fields in Compact Storage Rings, Nuclear Instruments & Methods in Physics Research/Section B, B30, Feb. 1988, No. 1, pp. 105-109. |
Moyers et al., A Continuously Variable Thickness Scatterer for Proton Beams Using Self-compensating Dual Linear Wedges Loma Linda University Medical Center, Dept. of Radiation Medicine, Loma Linda, CA, Nov. 2, 1992, 21 pages. |
National Cancer Institute Funding (Senat—Sep. 21, I 992} (wvw.tbomas.loc.gov/cgibin/querv/z?rl02:S21SE2-7l2 (2 pages). |
Nicholson, Applications of Proton Beam Therapy, Journal of the American Society of Radiologic Technologists, May/Jun. 1996, 67(5): 439-441. |
Nolen et al., The Integrated Cryogenic—Superconducting Beam Transport System Planned for MSU, Proceedings of the J21h International Conference on High-Energy Accelerators, Aug. 1983, pp. 549-551. |
Norimine et al., A Design of a Rotating Gantry with Easy Steering for Proton Therapy, Proceedings of EPAC 2002, 2002, pp. 2751-2753. |
Office Action for U.S. Appl. No. 14/137,854, 24 pages (dated Oct. 23, 2017). |
Office Action for U.S. Appl. No. 14/137,854, 32 pages (dated Dec. 22, 2016). |
Office Action for U.S. Appl. No. 14/937,048, 56 pages (dated Aug. 15, 2018). |
Office Action for U.S. Appl. No. 14/937,048, 94 pages (dated Oct. 13, 2017). |
Office Action for U.S. Appl. No. 15/399,250, 78 pages (dated Jan. 19, 2018). |
Office Action for U.S. Appl. No. 15/438,544, 27 pages (dated Oct. 12, 2017). |
Office Action for U.S. Appl. No. 14/137,854, 39 pages (dated Apr. 5, 2017). |
Ogino, Takashi, Heavy Charged Particle Radiotherapy-Proton Beam, Division of Radiation Oncology, National Cancer Hospital East, Kashiwa, Japan, Dec. 2003, 7 pages. |
Okumura et al., Overview and Future Prospect of Proton Radiotherapy, Japanese Journal of Cancer Clinics, 1997, 43(2):209-214 [Japanese, English Overview on p. 3]. |
Okumura et al., Proton Radiotherapy Japanese Journal of Cancer and Chemotherapy, 1993, 10. 20(14):2149-2155 [Japanese, English Abstract on p. 1]. |
Outstanding from Search Reports, Accelerator of Polarized Portons at Fermilab, 2005, 20 pages. |
Paganetti et al., Proton Beam Radiotherapy—The State of the Art, Springer Verlag, Heidelberg, ISBN 3-540-00321-5, Oct. 2005,36 pages. |
Palmer and Tollestrup, Superconducting Magnet Technology for Accelerators, Annual Review of Nuclear and Particle Science, 1984, vol. 34, pp. 247-284. |
Patent Assignee and Keyword Searches for Synchrocyclotron, Jan. 25, 2005, 78 pages. |
Patent Assignee Search Paul Scherrer Institute, Library Services at Fish & Richardson P.C., Mar. 20, 2007, 40 pages. |
Patent Prior Art Search for ‘Proton Therapy System’, Library Services at Fish & Richardson P.C., Mar. 20, 2007, 46 pages. |
Pavlovic, Beam-optics study of the gantry beam delivery system for light-ion cancer therapy, Nuclear Instruments and Methods in Physics Research, Section A, Nov. 1997, 399(2):439-454(16). |
Pedroni and Enge, Beam optics design of compact gantry for proton therapy Medical & Biological Engineering & Computing, May 1995, 33(3):271-277. |
Pedroni et al., A Novel Gantry for Proton Therapy at the Paul Scherrer Institute, Cycloctrons and Their Applications 2001: Sixteenth International Conference. AIP Conference Proceedings, 2001, 600:13-17. |
Pedroni et al., The 200-MeV proton therapy project at the Paul Scherrer Institute: Conceptual design and practical realization, Medical Physics, Jan. 1995, 22(1 ):37-53. |
Pedroni, Accelerators for Charged Particle Therapy: Performance Criteria from the User Point of View, Cyclotrons and their Applications, Proceedings of the 13th International Conference, Jul. 6-10, 1992, pp. 226-233. |
Pedroni, E. and Jermann, M. “SGSMP: Bulletin Mar. 2002 Proscan Project, Progress Report on the PROSCAN Project of PSI,” [online] retrieved from www.sgsmp.ch/protA23.htm, (5 pages) Mar. 2002. |
Pedroni, Latest Developments in Proton Therapy Proceedings of EPAC 2000, pp. 240-244, 2000. |
Pedroni, Status of Proton Therapy: results and future trends, Paul Scherrer Institute, Division of Radiation Medicine, 1994, 5 pages. |
Peggs et al., A Survey of Hadron Therapy Accelerator Technologies, Particle Accelerator Conference, Jun. 25-29, 2008, 7 pages. |
Potts et al., MPWP6-Therapy III: Treatment Aids and Techniques Medical Physics, Sep./Oct. 1988, 15(5):798. |
Pourrahimi et al., Powder Metallurgy Processed Nb3Sn(Ta) Wire for High Field NMR magnets, IEEE Transactions on Applied Superconductivity, Jun. 1995, 5(2):1603-1606. |
Prieels et al., The IBA State-of-the-Art Proton Therapy System, Performances and Recent Results, Application of Accelerators in Research and industry—Sixteenth Int'l Conj, American Institute of Physics, Nov. 1-5, 2000, 576:857-860. |
Proiect of PSI [online] retrieved from www.sgsmp.ch/protA23.htm, Mar. 2002, 5 pages. |
Rabin et al., Compact Designs for Comprehensive Proton Beam Clinical Facilities, Nuclear Instruments & Methods in Physics Research, Apr. 1989, Section B, vol. 40-41, Part II, pp. 1335-1339. |
Research & Development Magazine, Proton Therapy Center Nearing Completion, Aug. 1999, 41(9):2 pages (www.rdmag.com). |
Resmini Design Characteristics of the K=800 Superconducting Cyclotron at M.S.U., Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, IEEE Transaction on Nuclear Science, vol. NS-26, No. 2, Apr. 1979, 8 pages. |
RetroSearch Berkeley 88-Inch Cyclotron ‘RF’ or ‘Frequency Control’, Jan. 21, 2005, 36 pages. |
RetroSearch Berkeley 88-Inch Cyclotron, Jan. 24, 2005, 170 pages. |
RetroSearch Bernard Gottschalk, Cyclotron, Beams, Compensated Upstream Modulator, Compensated Scatter, Jan. 21, 2005, 20 pages. |
RetroSearch Cyclotron with ‘RF’ or ‘Frequency Control’, Jan. 21, 2005, 49 pages. |
RetroSearch Gottschalk, Bernard, Harvard Cyclotron Wheel, Jan. 21, 2005, 20 pages. |
RetroSearch Loma Linda University Beam Compensation, Jan. 21, 2005, 60 pages. |
RetroSearch Loma Linda University, Beam Compensation Foil Wedge, Jan. 21, 2005, 15 pages. |
Revised Patent Keyword Search, Jan. 25, 2005, 86 pages. |
Rifuggiato et, al., Status Report of the LNS Superconducting Cyclotron Nukleonika, 2003, 48:SI31-SI34, Supplement 2. |
Rode, Tevatron Cryogenic System, Proceedings of the 12th International Conference on Highenergy Accelerators, Fermilab, Aug. 11-16, 1983, pp. 529-535. |
Salzburger et al., Superconducting Synchrotron Magnets Supraleitende Synchrotronmagnete, NTiS, 155 pages (Oct. 1975). |
Schillo et al,. Compact Superconducting 250 MeV Proton Cyclotron for the PSI Proscan Proton Therapy Project, Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 37-39. |
Schneider et al., Nevis Synchrocyclotron Conversion Program—RF System, IEEE Transactions on Nuclear Science USA, Jun. 1969, ns 16(3): 430-433. |
Schneider et al., Superconducting Cyclotrons, IEEE Transactions on Magnetics, vol. MAG-11, No. 2, Mar. 1975, New York, pp. 443-446. |
Schreuder et al., The Non-orthogonal Fixed Beam Arrangement for the Second Proton Therapy Facility at the National Accelerator Centre, Application of Accelerators in Research and Industry, American Institute of Physics, Proceedings of the Fifteenth International Conference, Nov. 1998, Part Two, pp. 963-966. |
Schreuder, Recent Developments in Superconducting Cyclotrons, Proceedings of the 1995 Particle Accelerator Conference, May 1-5, 1995, vol. 1, pp. 317-321. |
Schubert and Blosser, Conceptual Design of a High Field Ultra-Compact Cyclotron for Nuclear Physics Research, Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, vol. 1, 3 pp. 1060-1062. |
Schubert et al., Progress toward an experiment to study the effect of RF grounding in an internal ion source on axial oscillations of the beam in a cyclotron, National Superconducting Cyclotron Laboratory, Michigan State University, Report MSUCL-760, CP600, Cyclotrons and their Applications 2011, Sixteenth International Conference, 2001, pp. 274-276. |
Schubert, Extending the Feasibility Boundary of the Isochronous Cyclotron, Dissertation submitted to Michigan State University, 1997, Abstract http://adsabs.harvard.edu/abs/1998PhDt . . . 147S. |
Shelaev et al., Design Features of a Model Superconducting Synchrotron of JINR, Proceedings of the 12th International Conference on High-energy Accelerators, Aug. 11-16, 1983, pp. 416-418. |
Shintomi et. al, Technology and Materials for the Superconducting Super Collider (SSC) Project, The Iron and Steel Institute of Japan 00211575, 78(8): 1305-1313, 1992, [English Abstract included]. |
Siemens A.G., Erlangen (West Germany). Abteilung Technische Physik, Report No. BMFT-FB-T-75-25, Oct. 1975, p. 147, Journal Announcement: GRAI7619; STAR1415, Subm-Sponsored by Bundesmin. Fuer Forsch. U. Technol. In German; English Summary. |
Sisterson, Clinical use of proton and ion beams from a world-wide perspective, Nuclear Instruments and Methods in Physics Research, Section B, 1989, 40-41:1350-1353. |
Sisterson, World Wide Proton Therapy Experience in 1997, The American Institute of Physics, Applications of Accelerators in Research and Industry, Proceedings of the Fifteenth International Conference, Part Two, Nov. 1998, pp. 959-962. |
Slater et al., Developing a Clinical Proton Accelerator Facility: Consortium-Assisted Technology Transfer, Conference Record of the 1991 IEEE Particle Accelerator Conference: Accelerator Science and Technology, vol. I, May 6-9, 1991, pp. 532-536. |
Slater et al., Development of a Hospital-Based Proton Beam Treatment Center, International Journal of Radiation Oncology Biology Physics, Apr. 1988, 14(4):761-775. |
Smith et al., The Northeast Proton Therapy Center at Massachusetts General Hospital Journal of Brachytherapy International, Jan. 1997, pp. 137-139. |
Snyder and Marti, Central region design studies for a proposed 250 MeV proton cyclotron, Nuclear Instruments and Methods in Physics Research, Section A, 1995, vol. 355, pp. 618-623. |
Soga, Progress of Particle Therapy in Japan, Application of Accelerators in Research and Industry, American Institute of Physics, Sixteenth International Conference, Nov. 2000, pp. 869-872. |
Source Search “Cites of U.S. and Foreign Patents/Published applications in the name of Mitsubishi Denki Kabushiki Kaisha and Containing the Keywords (Proton and Synchrocyclotron),” Jan. 2005, 8 pages. |
Spiller et al., The GSI Synchrotron Facility Proposal for Acceleration of High Intensity Ion and Proton Beams Proceedings of the 2003 Particle Accelerator Conference, May 12-16, 2003, vol. 1, pp. 589-591. |
Stanford et al., Method of Temperature Control in Microwave Ferroelectric Measurements, Sperry Microwave Electronics Company, Clearwater, Florida, Sep. 19, 1960, 1 page. |
Superconducting Cyclotron Contract awarded by Paul Scherrer Institute (PSI), Villigen, Switzerland, http://www.accel.de/News/superconducting_ cyclotron_ contract.htm, Jan. 2009, 1 page. |
Tadashi et al., Large superconducting super collider (SSC) in the planning and materials technology,78(8):1305-1313, The Iron and Steel Institute of Japan 00211575, Aug. 1992. |
Takada, Conceptual Design of a Proton Rotating Gantry for Cancer Therapy, Japanese Journal of Medical Physics, 1995, 15(4):270-284. |
Takayama et al., Compact Cyclotron for Proton Therapy, Proceedings of the 81h Symposium on Accelerator Science and Technology, Japan, Nov. 25-27, 1991, pp. 380-382. |
Teng, The Fermilab Tevatron, Coral Gables 1981, Proceedings, Gauge Theories, Massive Neutrinos, and Proton Decay, 1981, pp. 43-62. |
The Davis 76-Inch Isochronous Cyclotron, Beam On: Crocker Nuclear Laboratory, University of California, 2009, 1 page. |
The Journal of Practical Pharmacy,1995, 46(1):97-103 [Japanese]. |
The K100 Neutron-therapy Cyclotron, National Superconducting Cyclotron Laboratory at Michigan State University (NSCL ), retrieved from: http://www.nscl.msu.edu/tech/accelerators/kl 00, Feb. 2005, 1 page. |
The K250 Proton therapy Cyclotron, National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/tech/accelerators/k.250.html, Feb. 2005, 2 pages. |
The K250 Proton-therapy Cyclotron Photo Illustration, National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/media/image/ experimental-equipment-technology /25 0 .html, Feb. 2005, 1 page. |
Tilly, et al., Development and verification of the pulsed scanned proton beam at The Svedberg Laboratory in Uppsala, Physics in Medicine and Biology, Phys. Med. Biol. 52, pp. 2741-2454, 2007. |
Tobias, C.A., et al., Pituitary Irradiation with High-Energy Proton Beams A Preliminary Report, Cancer Research, vol. 18, No. 2, pp. 121-134 (1958). |
Tom, The Use of Compact Cyclotrons for Producing Fast Neutrons for Therapy in a Rotatable Isocentric Gantry, IEEE Transaction on Nuclear Science, Apr. 1979, 26(2):2294-2298. |
Torikoshi, M. et al., Irradiation System for HIMAC, J. Radiat. Res, 48: Suppl. A15-A25 (2007). |
Toyoda, Proton Therapy System, Sumitomo Heavy Industries, Ltd., 2000, 5 pages. |
Trinks et. al., The Tritron: A Superconducting Separated-Orbit Cyclotron, Nuclear Instruments and Methods in Physics Research, Section A, 1986, vol. 244, pp. 273-282. |
Tsuji, The Future and Progress of Proton Beam Radiotherapy, Journal of Japanese Society for Therapeutic Radiology and Oncology, 1994, 6(2):63-76. |
U.S. Appl. No. 13/830,792, filed Mar. 14, 2013, including the USPTO electronic file for U.S. Appl. No. 13/830,792. |
U.S. Appl. No. 13/949,459, filed Jul. 24, 2013, including the USPTO electronic file for U.S. Appl. No. 13/949,459. |
U.S. Appl. No. 61/676,377, filed Jul. 27, 2012, including the USPTO electronic file for U.S. Appl. No. 61/676,377. |
UC Davis School of Medicine, Unlikely Partners Tum Military Defense into Cancer Offense, Current Issue Summer 2008, Sacramento, California, pp. 1-2. |
Umegaki et al., Development of an Advanced Proton Beam Therapy System for Cancer Treatment Hitachi Hyoron, 2003, 85(9):605-608 [Lang.: Japanese], English abstract, http://www.hitachi.com/ICSFiles/afieldfile/2004/06/01/r2003_ 04_I 04.pdf or http://www.hitachi.com/rev/archive/2003/2005649_12606.html (full text) [Hitachi, 52( 4), Dec. 2003]. |
Umezawa et al., Beam Commissioning of the new Proton Therapy System for University of Tsukuba, Proceedings of the 2001 Particle Accelerator Conference, vol. 1, Jun. 18-22, 2001, pp. 648-650. |
Van Steenbergen, Superconducting Synchroton Development at BNL, Proceedings of the 8th International Conference on High-Energy Accelerators CERN 1971, 1971, pp. 196-198. |
Van Steenbergen, The CMS, a Cold Magnet Synchrotron to Upgrade the Proton Energy Range of the BNL Facility, IEEE Transactions on Nuclear Science, Jun. 1971, 18(3):694-698. |
Vandeplassche et al., 235 MeV Cyclotron for MGH's Northeast Proton Therapy Center (NPTC): Present Status, EPAC 96, Fifth European Partical Accelerator Conference, vol. 3, Jun. 10-14, 1996, pp. 2650-2652. |
Vorobiev et al., Concepts of a Compact Achromatic Proton Gantry with a Wide Scanning Field, Nuclear Instruments and Methods in Physics Research, Section A., 1998, 406(2):307-310. |
Vrenken et al., A Design of a Compact Gantry for Proton Therapy with 2D-Scanning, Nuclear Instruments and Methods in Physics Research, Section A, 1999, 426(2):618-624. |
Wikipedia, Cyclotron http://en.wikipedia.org/wiki/Cyclotron (originally visited Oct. 6, 2005, revisited Jan. 28, 2009), 7 pages. |
Wikipedia, Synchrotron http://en.wikipedia.org/wiki/Synchrotron (originally visited Oct. 6, 2005, revisited Jan. 28, 2009), 7 pages. |
Worldwide Patent Assignee Search, Jan. 24, 2005, 224 pages. |
Worldwide Patent Keyword Search, Jan. 24, 2005, 94 pages. |
Written Opinion for PCT/US2016/048037, 12 pages (dated Feb. 6, 2017). |
Written Opinion for PCT/US2017/067677 (High-Speed Energy Switching, filed Dec. 20, 2017), issued by ISA/US, 7 pages (dated Apr. 30, 2018). |
Wu, Conceptual Design and Orbit Dynamics in a 250 MeV Superconducting Synchrocyclotron, Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1990, 172 pages. |
York et al., Present Status and Future Possibilities at NSCL-MSU, EP AC 94, Fourth European Particle Accelerator Conference, pp. 554-556, Jun. 1994. |
York et al., The NSCL Coupled Cyclotron Project—Overview and Status, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 1998, pp. 687-691. |
Yudelev et al., Hospital Based Superconducting Cyclotron for Neutron Therapy: Medical Physics Perspective, Cyclotrons and their applications 2001, 16th International Conference. American Institute of Physics Conference Proceedings, vol. 600, May 13-17, 2001, pp. 40-43. |
Zherbin et al., Proton Beam Therapy at the Leningrad Synchrocyclotron (Clinicomethodological Aspects and Therapeutic Results), Aug. 1987, 32(8):17-22, (German with English abstract on pp. 21-22). |
Second Office Action (Chinese translation) for CN201480070002.6, 3 pages (dated Jan. 11, 2019). |
Second Office Action (English translation) for CN201480070002.6, 4 pages (dated Jan. 11, 2019). |
Final Office Action for U.S. Appl. No. 15/438,854, 30 pages (dated Nov. 28, 2018). |
Final Office Action for U.S. Appl. No. 15/438,863, 30 pages (dated Nov. 28, 2018). |
International Search Report for PCT/US2018/040211 (Configurable Collimator Controlled Using Linear Motors, filed Jun. 28, 2018), issued from ISA/EP, 6 pages (dated Nov. 16, 2018). |
Office Action for U.S. Appl. No. 15/399,250, 8 pages (dated Jan. 24, 2019). |
Written Opinion for PCT/US2018/040211 (Configurable Collimator Controlled Using Linear Motors, filed Jun. 28, 2018), issued from ISA/EP, 8 pages (dated Nov. 16, 2018). |
Number | Date | Country | |
---|---|---|---|
20190001153 A1 | Jan 2019 | US |
Number | Date | Country | |
---|---|---|---|
62527539 | Jun 2017 | US |